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Executive summary
Otto Hänninen and Anne Knol (Eds.). EBoDE-Report. Environmental Perspectives on Environmental 
Burden of Disease. Estimates for Nine Stressors in Six European Countries. National Institute for Health 
and Welfare (THL), Report 1/2011. 86 pages and 2 appendixes. Helsinki, Finland 2011. ISBN 978-952-245-
412-6 (printed), ISBN 978-952-245-413-3 (PDF)
The highest environment-related health benefits can be expected from policies that efficiently target 
environmental exposures having high contributions to the burden of disease (BoD) in the population. 
Such benefits are demonstrated for example by the smoking bans in public places that have shown 
significant population health improvements in many European countries. However, the health impacts 
of environmental stressors range from relatively mild psychological effects like annoyance to effects on 
morbidity such as asthma, cardiovascular diseases, cancer and premature mortality. This diversity of 
health effects challenges the comparison of the impacts of alternative policies.
The objectives of the multinational European EBoDE-project (Environmental Burden of Disease in 
the European region) included updating previous environmental burden of disease (EBD) assessments, 
identifying stressors relevant for the European region, testing a harmonized EBD methodology in the 
participating countries, and developing and making available the methodology for other countries. The 
project has assessed the environmental burden of disease related to nine selected stressors across six 
countries: Belgium, Finland, France, Germany, Italy and the Netherlands. The assessed stressors were: 
benzene, dioxins (including furans and dioxin-like PCBs), non-smokers exposure to second-hand smoke, 
formaldehyde, lead, transportation noise (including road, rail and air traffic), ozone, particulate matter 
(PM
2.5
) and radon. The stressors were selected based on their public health relevance, potential for high 
individual risks, public concern and/or large economical impacts. 
The environmental burden of disease is expressed in Disability Adjusted Life Years (DALYs), which are 
a summary measure of population health combining mortality and morbidity. Calculations were based on 
the most recent scientific evidence concerning population exposure and health effects, national exposure 
data and WHO burden of disease data.
Even though the most recent scientific knowledge and data were used, many uncertainties and 
controversies remain. Results give only a crude ranking of environmental health impacts and need to be 
interpreted with caution. The results suggest that 3–7% of the burden of disease1 in the participating six 
countries is associated with the selected nine environmental stressors. Particulate matter (PM) is estimated 
to be associated with the highest disease burden (6 000 to 10 000 DALYs per million people2), followed by 
second-hand smoke, traffic noise and radon. 
Burden of disease estimates quantify the attributable health impacts of environmental exposures. 
However, due to background exposures from natural sources and practical limitations in removing 
anthropogenic pollution, the total attributable burden of disease cannot be directly interpreted as 
reduction potential. EBD estimates can be used to identify areas of high disease burden for more detailed 
analysis of the reduction potential by targeted policies. Quantitative methods like EBD and health impact 
assessment should be used to inform policy makers about the health benefits of specific policy measures. 
Keywords:  Environmental burden of disease, disability adjusted life years (DALY), benzene, dioxins, 
second hand smoke, formaldehyde, lead, transportation noise, ozone, particulate matter (PM
2.5
), radon, 
Belgium, Finland, France, Germany, Italy, The Netherlands
1 Discounted and age-weighed according to the standard procedure (WHO, 2010a).
2 Non-discounted and non-age-weighed values.
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Abbreviations 
ALRI  Acute lower respiratory infection
AM  Arithmetic mean 
BOD  Burden of disease
B-Pb  Blood lead concentration 
COPD  Chronic obstructive pulmonary disease; group of related pulmonary diseases, most common 
form chronic bronchitis
DALY  Disability adjusted life year; burden of disease metric that combines years of life lost and years 
lived with disabilities (DALY=YLL+YLD)
dB(A)  Decibel (A-frequency weighing). Measure of noise level
DW  Disability weight, parameter used in defining magnitude associated with years lived with 
disability
EBD Environmental burden of disease; BoD associated with defined environmental causes
END European Noise Directive
ERF Exposure-response function
GBD Global Burden of Disease (WHO assessment)
GM Geometric mean
GSD Geometric standard deviation
HSD High sleep disturbance; health endpoint associated with environmental noise exposures
HTD Hypertensive disease
ICT Impact calculation tool, probabilistic modelling tool run in Analytica environment
IHD Ischaemic heart disease
IQ Intelligence quotient
L
day
 Weighted noise level for daytime
L
den
 Weighted noise level for day-evening-night 
LE Life expectancy
L
night
 Weighted noise level for nighttime
LRS Lower respiratory symptoms
MI Myocardial infarction
MMR Mild mental retardation
MRAD Minor restricted activity days; health outcome defined in CAFE study for ozone
OR Odds ratio
PAF Population attributable fraction
PCB Polychlorinated biphenyls, a chemical group of toxic compounds
PM
10
  Particulate matter with aerodynamic particle diameter smaller than 10 µm
PM
2.5
 Particulate matter with aerodynamic particle diameter smaller than 2.5 µm
RAD Restricted activity days; health outcome defined in CAFE study for particulate matter
RR  Relative risk expressed either for the prevailing exposure level (in cohort studies) or normalized 
for a selected unit exposure, e.g. per 10 µg m-3 
SD Standard deviation
SHS Second hand smoke; sometimes called also environmental tobacco smoke (ETS)
TEQ  Toxicity equivalent; a metric expressing the toxicity of a mixture of dioxins and PCBs as an 
equivalent amount of the most toxic compound, TCDD (original set of toxicity equivalency 
factors by WHO 1998, updated in 2005)
UR Unit risk; population risk per an individual and unit exposure
YLD Years lived with disability, a component of disease burden measured as DALYs
YLL Years of life lost, a component of disease burden measured as DALYs
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1 Overview of the EBoDE-project
1.1 Introduction
Exposures to many environmental stressors are known to endanger human health. Negative impacts on 
health can range from mild psychological effects (e.g. noise annoyance), to effects on morbidity (such as 
asthma caused by exposure to air pollution), and to increased mortality (such as lung cancer provoked 
by radon exposure). Properly targeted and followed-up environmental health policies, such as the coal 
burning ban in Dublin (1990) and the smoking ban in public places in Rome (2005) have demonstrated 
significant and immediate population level reductions in deaths and diseases. In order to develop effective 
policy measures, quantitative information about the extent of health impacts of different environmental 
stressors is needed. 
As demonstrated by the examples above, health effects of environmental factors often vary 
considerably with regard to their severity, duration and magnitude. This makes it difficult to compare 
different (environmental) health effects and to set priorities in health policies or research programs. Public 
health policies generally aim to allocate resources effectively for maximum health benefits while avoiding 
undue interference with other societal functions and human activities. In order to develop such policies, it 
is necessary to know what ‘maximum health benefits’ are. Decades ago, such decisions tended to be made 
based on mortality statistics: which (environmental) factor causes most deaths? However, nowadays, most 
people get relatively old, and priority has shifted from quantity to quality of life. This has lead to the need 
to incorporate morbidity effects into public health decisions, and therefore to find a way of comparing 
dissimilar health effects. 
Such comparison and prioritisation of environmental health effects is made possible by expressing the 
diverging health effects in one unit: the environmental burden of disease (EBD). Environmental burden of 
disease figures express both mortality and morbidity effects in a population in one number. They quantify 
and summarize (environmental) health effects and can be used for:
• Comparative evaluation of environmental burden of disease (“how bad is it?”) 
•	 Evaluation of the effectiveness of environmental policies (largest reduction of disease burden) 
•	 Estimation of the accumulation of exposures to environmental factors (for example in urban areas)
•	 Communication of health risks
An example of an integrated health measure that can be used to express the environmental burden of 
disease is the DALY (Disability Adjusted Life Years). DALYs combine information on quality and quantity 
of life. They give an indication of the (potential) number of healthy life years lost in a population due to 
premature mortality or morbidity, the latter being weighted for the severity of the disorder. The concept 
was first introduced by Murray and Lopez (1996) as part of the Global Burden of Disease study, which 
was launched by the World Bank. Since then, the World Health Organization (WHO) has endorsed the 
procedure, and the DALY approach has been used in various studies on a global, national and regional 
level.
WHO collects a vast set of data on the global burden of disease. The first study quantified the health 
effects of more than 100 diseases for eight regions of the world in 1990 (Murray and Lopez, 1996). It 
generated comprehensive and internally consistent estimates of mortality and morbidity by age, gender 
and region. In a former WHO study, it was shown that almost a quarter of all disease worldwide was 
caused by environmental exposure (Prüss-Üstün and Corvalán, 2006). In industrial sub-regions this 
estimate was about 16% (15–18%). These fractions, however, are dependent on the conclusiveness of the 
included environmental factors and health effects. The WHO programme on quantifying environmental 
health impacts has addressed more than a dozen stressors (http://www.who.int/quantifying_ehimpacts/
publications/en/). In order to support further applications of the environmental burden of disease (EBD) 
1   Overview of the EBoDE-project
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assessments, a methodological guidance has been published by WHO (Prüss-Üstün et al., 2003) and was 
followed here too.
In Europe, national environmental burden of disease (EBD) assessments are on-going in several 
countries. The work by RIVM was one of the first systematic European works in this area that utilized 
disability-adjusted life years (DALY) as a measure to compare the burden of different health outcomes 
related to the exposure of the population to environmental stressors (Hollander et al., 1999). The results 
highlighted that (i) a number of environmental stressors may cause chronic or acute diseases or death, (ii) 
a few top ranking stressors cause over 90% of the national EBD, and (iii) these top ranking stressors are 
not necessarily those that have drawn the most concern, regulatory action and/or preventive investment.
1.2 Objectives
The EBoDE-project was set up in order to guide environmental health policy making in the six participating 
countries (Belgium, Finland, France, Germany, Italy and the Netherlands) and potentially beyond. From 
a policy perspective, these insights from the EBoDE-project can be useful to evaluate past policies and to 
gain insight in setting the policy priorities for the future. We have calculated the total EBD associated with 
the nine environmental stressors. The total EBD is not identical to the avoidable burden of disease, because 
some exposures are not realistically reducible to zero (e.g. fine particles). Also, our estimates do not take 
into account the costs of reducing the EBD. Thus, the results are only one input into the full process of 
developing cost-effective policies to achieve better environmental health.
The objectives of the project were to update the available previous assessments, to focus on stressors 
relevant for the European region, to provide harmonized EBD assessments for participating countries, and 
to develop and make available the methodologies for further development and other countries. 
The specific objectives are to: 
• Provide harmonized environmental burden of disease (EBD) estimates for selected environmental 
stressors in the participating six countries;
•	 Test the methodologies in a harmonized way across the countries.
•	 Assess the comparability of the quantifications and ranking of the EBD 
•	 between countries
•	 within countries
•	 between environmental stressors;
•	 Qualitative assessments of variation and uncertainty in the input parameters and results.
Environmental burden of disease estimates have been calculated for:
•	 nine environmental stressors: benzene, dioxins (including furans and dioxin-like PCBs), second-
hand smoke, formaldehyde, lead, noise, ozone, particulate matter (PM) and radon;
•	 six European countries: Belgium, Finland, France, Germany, Italy and the Netherlands;
•	 the year 2004 (and some trend estimates for the year 2010).
As outlined above, the EBoDE study was carried out in order to test the environmental burden of disease 
methodology in various countries. The results of the studies are intended to allow comparison of the disease 
burden between different environmental stressors and between countries. Consequently, the study does 
not to identify the ‘reduction potential’. Our estimates should therefore not be interpreted as the ‘avoidable 
burden of disease’: most risks cannot realistically be completely removed by any policy measures. For some 
exposures, however, the numbers may nonetheless be interpretable as reduction potential, eg for dioxins, 
formaldehyde, benzene, etc, as these exposures could potentially be completely eliminated.
1   Overview of the EBoDE-project
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1.3 Outline of this report
This report describes the methods, data and results of the EBoDE-project. Chapter 2 presents the 
methodology. The environmental stressors are introduced in Chapter 3, which also presents the data used 
(selected health endpoints, exposure data, exposure response functions). In Chapter 4, the results are 
presented and discussed. Chapter 5 gives information about uncertainties in the approach, and provides 
some alternative calculations using different input values. In Chapter 6 conclusions are drawn. The report 
ends with the references and two appendices: Appendix A presents country-specific results and Appendix 
B some considerations for using a life-table approach in EBD modelling.
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2 Methods: Environmental burden of   
 disease calculation
This chapter provides information about methods to calculate the environmental burden of disease, 
and the assumptions and choices that need to be made. Table 2-1 provides an overview of these baseline 
assumptions underlying the calculations as performed in the EBoDE project. The remainder of this 
chapter describes the specific models used for calculating the EBD and explains the different parameters 
and data used. 
TABLE 2-1. Baseline facts and assumptions underlying environmental burden of disease calculations as carried out in 
the EBoDE project.
Parameter of 
assumptions
Choice made Motivation Remarks
Year 2004 Most recent year with 
relatively good data 
availability
Exposure trends were 
evaluated till 2010 for a 
qualitative policy analysis
Environmental 
stressors
Benzene, dioxins (including 
furans and dioxin-like 
PCBs), second-hand smoke, 
formaldehyde, lead, noise, 
ozone, particulate matter 
(PM) and radon
Based on selection criteria See section 3.1
Countries Belgium, Finland, France, 
Germany, Italy and the 
Netherlands
Integration of national 
projects 
EBoDE working group and 
methodology is open for 
other countries
Age weighing 
& discounting 
Main results without 
discounting and age-
weighing; alternative results 
with discounting (3%) and 
age-weighing (standard)
Ethical reasons. 
Supplementary discounted 
and age-weighed results 
presented for comparability 
with WHO estimates
See section 2.3
Standard Life 
Expectancy
80 years for men and 82.5 for 
women
Comparability with WHO 
estimates
See for exceptions section 2.2.
Lag time Calculations carried out with 
and without lag times 
For certain diseases there is a 
relatively long lag between 
exposure and the effect. 
When using discounting, the 
lag should be accounted for
Lag times are based on 
author judgement and serve 
as rough estimates (see 
section 3.11)
Uncertainty 
analyses
Qualitative and partly 
quantitative
It is essential to assess 
whether the substantial 
inherent uncertainties affect 
the order of magnitude of 
the results or the ranking of 
stressors
Data availability and limited 
resources allowed only 
for qualitative approach. 
Additional quantitative 
analyses are recommended as 
a part of follow-up research 
(see section 2.4 and Chapter 
5)
Multi-causality Not adjusted Lack of knowledge/ data See section 2.2
Co-morbidity Not adjusted Lack of knowledge/ data See section 2.2
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2.1 Basic calculation of the environmental burden of    
 disease 
The DALY measures health gaps (i.e. years of life lost due to death or disability) as opposed to health 
expectancies. It measures the difference between a current situation and an ideal or alternative situation. 
The DALY combines the time lived with disability and the time lost due to premature mortality in one 
measure:
DALY = YLL + YLD
Years of Life Lost (YLL) in a case of individual death is calculated as the difference between the standard 
life expectancy at the age of death and the actual age at death. When population data is tabulated for age 
categories, YLL can be calculated as:
L = LE (age
death
, gender) -age
death
The basic formula for calculating 
the population-wide YLL is:
YLL = N x L
Methods for calculating YLL are 
further described in section 2.2.
To estimate the Years Lost due to Disability (YLD), the number of disability cases is multiplied by the 
average duration of the disease and a disability weight (see further discussion below). The basic formula is:
YLD = n x DW x L 
The formulas above describe undiscounted, non-weighted DALYs. DALYs are sometimes attributed a 
discounting rate, and weightings according to age, in which case the formulas become more complex. 
These so-called social preferences are discussed in section 2.3.
2.1.1 Disability weights (DW)
Disability weights are used to make different health effects with varying degrees of severity comparable. 
They are weight factors that reflect the severity of the disease on a scale from 0 (perfect health) to 1 
(equivalent to death). These factors have been determined in expert panels using standardized surveys.
2.1.2 Duration estimates (L)
Besides disability weights, estimates of DALYs for morbidity (Years Lost due to Disability – YLD) also take 
into account the duration of the disease derived from health statistics, registries, expert judgments, etc. In 
some cases, prevalence data are used in burden of disease calculations instead of incidence data. In that 
case, the durationof disease is set to 1 year in the calculation, assuming a steady-state situation in which 
prevalence equals incidence times duration. For mortality, the duration estimate equals the YLL (Years of 
Life Lost, see section 2.2).
where:
YLL = Years of Life Lost due to premature mortality.
YLD = Years Lost due to Disability.
where:
LE(age,gender) = life-expectancy at age of death, accounting for 
gender
age
death
 = age at death
N = number of deaths in a given age category
L = remaining years to standard life expectancy at age of death (in 
years).
where:
YLD = Years Lost due to Disability
n = number of incident cases.
DW = disability weight.
L = average duration of disability (years) 
2   Methods: Environmental burden of disease calculation
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2.1.3 Models for estimating the environmental burden of disease 
The general methodology for the environmental burden of disease calculations as carried out in EBoDE 
follows the Comparative Risk Assessment Approach (Ezzati et al., 2002; Prüss-Üstün et al. 2003). In general, 
information about population exposure, an exposure response function and (in some cases) background 
incidence data are needed in order to estimate the environmental burden of disease (EBD).
In EBoDE, three different methods for deriving the EBD are used. They are presented in Figures 2-1a 
and 2-1b (methods 1A, 2A and 2B). Model 1B is not used in EBoDE, but complements the other three 
methods. The methods differ in how they derive the population attributable fraction (using a unit risk 
(UR) or a relative risk (RR) – see Textbox 1), and in whether burden of disease figures are derived from the 
WHO database or estimated using disability weights (DW) and duration factors (L). 
• Model 1A is the primary model used in EBoDE. Exposure data and a relative risk derived from 
epidemiological data are used to derive the population attributable fraction (PAF). This fraction is 
applied to the burden of disease figures as given in the WHO global burden of disease database.
•	 In model 2A, the PAF is derived indirectly. The unit risk and exposure information are used to estimate 
the attributable incidence (AI). The PAF is indirectly estimated from dividing the total incidence by 
this AI. Subsequently, the PAF is applied to the WHO burden of disease data for both YLL and YLD.
•	 In model 2B, the AI is derived similarly as in model 2A. However, for the factors for which this 
approach has been used, no appropriate burden of disease data were available from WHO and the 
EBD was calculated by multiplying the estimated number of attributable cases with WHO disability 
weights (DW) and corresponding estimates of duration (L).
•	 Model 1B, which was not used in EBoDE, could be used when the PAF is derived using a RR risk, and 
the EBD is calculated using disability weights (DW) and estimates of duration (L).
The conceptual basis of the different methods is the same. Which exact method is chosen for a specific 
calculation mainly depends on the available data. In principle, these different means should come to the 
same end. If one would use all different approaches for the same calculation,  they would ideally result in 
the same number. However, in reality it is hardly ever possible to perform all these different calculations 
because of unavailability of data. Even if possible, the different methods will rarely result in the same 
number. This stresses the importance of interpreting burden of disease figures as crude ranges and not 
as absolute infallible numbers. More information about uncertainty is presented in section 2.4 and in 
Chapter 5. 
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The UR gives the absolute number of cases that are to be expected at a certain exposure, and can be derived for 
effects which are independent of the background disease rate. The number of cases is directly estimated based 
on exposure (number of people exposed) multiplied by the unit risk estimate.
Odds ratio is the ratio of the odds of a disease occurring in the exposed group to the odds of it occurring in the 
non-exposed group. OR is typically estimated in epidemiological studies, where the study groups are selected by 
their exposure status and thus the ratio of exposed does not directly reflect the corresponding fraction in the 
general population. However, when the disease prevalence in the non-exposed population is relatively low (<10 
%), OR can be used as an estimate of the relative risk (RR).
* The definition for RR provided here is valid for the prevailing exposure levels. In contrast, most of the RR values used in 
the calculations are expressed per selected unit exposure, e.g. 10 µg m-3. 
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Textbox 1: Relative Risk, Unit Risk and Odds Ratio
Exposure response functions can take many forms, dependent on the type of 
relation between the exposure and the health effect, and the type of study 
used to derive it. In EBoDE, we use relative risks (RR), unit risks (UR) and some 
more complex functions (not further discussed here).
The RR* is defined as the risk of developing a disease (the event) 
relative to exposure, expressed as the ratio of the probability of 
the event occurring in the exposed group versus a non-exposed 
group
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FIGURE 2-1a. Relative risk models to estimate the environmental burden of disease. Model 1b (greyed) is not used in EBoDE.
A: Applying the PAF to total burden of disease data  
(WHO database)
 
B: Calculating the Burden of Disease:
 AI x DW x L
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FIGURE 2-1b. Unit risk models to estimate the environmental burden of disease. 
A: Applying the PAF to total burden of disease data  
(WHO database)
 
B: Calculating the Burden of Disease:
 AI x DW x L
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2.2 Years of Life Lost, co-morbidity and multi-causality
DALY calculations for mortality outcomes include an estimate of the Years of Life Lost, i.e. the number of 
years a person would have continued to live, had this person not died due to the environmental exposure. 
In the WHO Global Burden of Disease programme and in the current work a standard life expectancy, 
defined as a population with highest known life-expectancy, is used. This ensures that all populations 
globally are treated equally when addressing the disease burden. 
However, in the current context where the focus is set on specific environmental causes of burden of 
disease, it can be argued that if all environmental causes of burden of disease were removed, the population 
in question still would not reach this optimal life expectancy. This is due to the fact that all factors affecting 
the population health (including also genetic factors, lifestyle, the health care system, etc.) contribute 
to the national life expectancy. Thus it could be argued that a national life expectancy should be used 
in estimating the impacts of given single factors. This difference in approaches is highlighted in Figure 
2-2. In the EBoDE project we have chosen to use the standard life expectancy in order to allow for better 
comparison between countries.Figure 2-2. Estimating the years of life lost due to lung cancer.
2.2.1 Co-morbidity
Co-morbidity can play a role in estimating DALYs for morbidity. In the case of co-morbidity, people are 
not only affected by the disease under scrutiny, but are also weakened by other conditions. In industrialised 
countries, older people often have more than one disease. Severity weights do not take account of these co-
morbid conditions (Gold et al., 2001). The disease burden is disease-specific and not individual specific, 
so adding up the severity weights for all diseases in a person could result in a weight of more than one, 
representing a state worse than death (Anand and Hanson, 1997; Schneider, 2001). Effects of co-morbidity 
can be relevant when looking at one person with several diseases. However, when estimating the burden of 
disease for a complete population, the effect of co-morbidity is not very influential.
0 10 20 30 40 50 60 70 80 90
(1) Years of life lost due to a lung cancer death, on average,
in comparison with the national age-specific life expectancy
(2) Years of life lost due to all causes of death, on average,
in comparison with the life expectancy in Japan (longest
living population)
(3) Loss of national life expectancy due to the specific cause:
National life expectancy would be marginally higher without
the target disease, lung cancer in the example (magnitude
not in scale)
Average cause specific
age of death
National life expectancy
Life expectancy
in Japan
Death at age of 71
Years of life lived
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2.2.2 Multi-causality
Multi-causality means that people have a single disease, but that this disease is caused by multiple factors. 
People may for example have lung cancer due to a combined effect of radon and smoking. If the exposure 
to radon would be removed, part of the lung cancer cases could be prevented. However, partly the same 
cases could in principle be prevented by quitting smoking. Because of this effect, which is called multi-
causality, the estimated attributable fractions of these two separate causes for lung cancer are potentially 
additive to more than 100%. Therefore, there may be overlap in the estimated disease burdens of these 
two factors and they can not be summated without correction for this overlap. In case of mortality, this 
concept is also referred to as ‘competing causes of death’. 
Correcting for multi-causality is most important when a significant number of cases are indeed caused 
by several of the addressed risk factors. It is however difficult to estimate exact effect of multi-causality, 
as the underlying epidemiology is lacking in many instances. In this project, multi-causality may affect 
the health impacts related to the joint exposure to outdoor air pollution and second-hand smoke, or to 
second-hand smoke and radon. The potential effect of multi-causality and overlapping health endpoints 
is not corrected for in our estimates of the burden of disease, but is discussed in the respective chapters. 
The stressor-specific figures should be interpreted as the burden of disease that could theoretically be 
prevented if the specific risk factor was removed.
 
2.3 Discounting, age-weighing and lag times
The environmental burden of disease estimated in EBoDE as DALYs are expressed in three alternative 
metrics. The differentiating weighing factors are described shortly in this chapter. The three metrics we 
used are:
• non-discounted, non age-weighted DALYs (i.e. health impacts occurring later in the future are 
counted with similar weight as immediate effects; health effects are weighted the same at all ages; no 
lag times are included)
•	 discounted and age-weighted DALYs (i.e. future health impacts are brought to present value assuming 
a constant discount rate of 3%; health impacts in older and younger people are age-weighted using 
the standard WHO procedure; no lag times are included)
•	 discounted and age-weighted DALYs with lag (i.e. future health impacts are brought to present value 
assuming a constant discount rate of 3%; health impacts in older and younger people are age-weighted 
and the delay from current exposure to the manifestation of the associated disease, e.g. cancer (lag) is 
included in the discounting procedure).
2.3.1 Discounting
When DALYs are discounted, future years of healthy life are valued less than present years. Discounting is 
based on the fact that people generally seem to prefer a healthy year of life immediately over a year of life 
lived in the future. In its Global Burden of Disease study, WHO applies a 3% time discount rate to years 
of life lost in the future. This means that a year of healthy life gained 10 years from now is worth 24% less 
than a year gained now. The use of discount rates can also be debated. Applying discounting to burden of 
disease figures is not favourable for children and future generations (Anand and Hanson, 1997; Arnesen 
and Nord, 1999) and preventive measures are devalued, as they cost money now while benefits will become 
apparent later (Schneider, 2001). 
2.3.2 Age weighing
In the GBD study as done by WHO, a year of healthy life lived at younger and older ages is weighted lower 
than for other ages (see Figure 2-3). The motivation for such age-weighing is a number of studies that 
have indicated a social preference to value a year lived by a young adult more highly than a year lived by 
a young child, or lived at older ages. The social value of middle-age groups is considered to be greater, 
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due to responsibility for their dependants, than the value of younger or older people. However, the use of 
age weights is highly controversial. Some critics state that it is unethical to value the lives of children and 
elderly less than other lives (Arnesen and Nord, 1999; Anand and Hanson, 1997; Schneider, 2001). 
FIGURE 2-3. Relative value of a year of life lived, by age: reported preferences and modelling. A 3% discount rate 
is used by WHO. (Adapted from Figure 3.1 in the WHO document. http://www.who.int/quantifying_ehimpacts/
publications/en/9241546204chap3.pdf)
2.3.3 Discounting and age-weighing in EBoDE
The choices made for discounting, age weighing and the severity weights chosen can lead to large 
differences in DALYs. Alternative but still realistic assumptions for all these parameters can lead to chances 
up to a factor of four (Arnesen & Kapiriri, 2004). In recognition of the non-favourable aspects of age-
weighing and discounting as outlined above, our main results are presented without any discounting or 
age-weighing. However, in order to make EBoDE results comparable to other WHO burden of disease 
estimates, we have also calculated our results using age-weighing and discounting (3%). 
2.3.4 Lag times
Certain health impacts like cancer and chronic diseases develop slowly and the outbreak of the disease 
occurs years or decades later than the exposure associated with it. These lag-times are not commonly 
included in burden of disease calculations even though when discounting is used, any delays in the impact 
will affect also the discounted present value of the impact.
To complement the standard discounting approach in the EBoDE project, we have tested the effect of 
lag-times on discounted DALYs. Only the effect of increased discounting due to lag-times is included (so 
changing population dynamics over time are not taken into account). The lag times used in EBoDE are 
presented in the Data chapter (section 3.11).
2.4 Uncertainty analysis
Many factors contribute to the uncertainty in burden of disease estimates. Besides uncertainties caused 
by differences or inconsistencies in the methodological approaches and assumptions discussed above, 
also the basic data on population exposures contain uncertainties. In addition, our knowledge about 
environmental health impacts is incomplete, and a variety of assumptions need to be made, including 
assumptions about causality and exposure-response relationships. For the formal discussion of these 
factors we will use the framework presented by Knol, 2009, and distinguish between context uncertainty 
(i.e. the boundaries of the assessment, the definitions used, the selected stressors and health endpoints, 
etc), model structure uncertainty (i.e. for example uncertainty about causality) and parameter and input 
data uncertainty (i.e. confidence intervals of exposure response functions or inconsistent health statistics). 
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In EBoDE, qualitative and partly quantitative methods were used to estimate the impact of various 
sources of uncertainty in the estimates. The following sources of uncertainties were taken into account: 
Context uncertainty:
• Selection of exposure metric
•	 approximating particulate matter exposures with PM
2.5
 or PM
10
•	 indoor versus outdoor concentrations versus personal exposure versus doses
•	 Selection of health endpoints
•	 Dioxins: total cancers versus more specific health endpoints
•	 Lead: hypertension versus cardiovascular endpoints
•	 Road transport noise: Myocardial Infarction versus Ischemic Heart Disease
•	 Estimation of policies and trends from 2004 to 2010
Model structure uncertainty:
•	 Comparison between alternative model approaches
•	 Unit risk and Relative Risk models for Radon
•	 Formaldehyde: models for asthma and cancer using different thresholds
•	 Probabilistic versus deterministic modelling (ICT vs. Excel, see section 2.5 and Appendix B)
Input data and parameter uncertainty:
•	 Statistical confidence intervals for the exposure-response model parameters
•	 Deficiencies in the representativity of the noise exposure data 
•	 Qualitative analysis of population representativity of exposure data 
•	 Temporal representativity of the exposure data (e.g. lead estimation from data from 1990’s; SHS trend 
model) 
•	 Comparison of PM
2.5
 and ozone models with earlier CAFE estimates (exposure data updated using 
new estimation methods)
•	 Estimation of noise L
night
 levels from L
den
 levels (see section 3.7): comparison for countries with both 
variables reported 
The impact of the uncertainties on the results is discussed in Chapter 5, which also presents a table with 
the most important sources of uncertainty for each stressor. More thorough uncertainty and sensitivity 
analysis is recommended for the potential follow-up work using for example probabilistic modelling, such 
as the Impact Calculation Tool (see the Appendix B). 
2.5 Software
Model calculations were completed in a number of Excel models based on deterministic point value 
estimates of the various input parameters. Variability and uncertainty calculations were conducted using 
95% confidence intervals of the exposure-response relationships. Exposure distribution estimates (for 
formaldehyde and lead) were conducted using Risk 4.0 (Palisade Corp., NY) simulation and probabilistic 
distribution calculations using the Excel worksheet functions for normal distributions. 
The Excel sheets used in the EBoDE project do not contain distributional uncertainty or sensitivity 
analyses. In addition, they are not using life tables in order to model changes in population demographics 
that may affect health effects in the future. In Appendix B we discuss the use of a probabilistic model called 
Impact Calculation Tool (ICT), developed in collaboration by THL and RIVM, which includes many of 
the above mentioned features. It was not yet fully developed when EBoDE calculations were carried out, 
but can be used for future health impact assessment studies. Some test calculations were performed and 
the comparisons did not indicate changes in the main conclusions and recommendations. Use of life-
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tables would require more elaborate definitions of the causal associations, e.g. the duration from exposure 
to outbreak of the disease (the lag-time) that were modelled here with simpler methods. 
For selected stressors, EBoDE results were compared with results obtained using the ICT, thereby 
comparing a probabilistic life-table approach with deterministic point value calculations. The two 
approaches are compared in Appendix B.
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3 Selected exposures and health effects
This chapter presents, for each stressor, the health effects included in our analyses, exposure response 
functions that were used and the exposure data. Table 3-19 presents an overview of the selected 
environmental stressors, health endpoints, exposure-response functions and methods used. An overview 
of exposure data used for each stressor is given in Table 3-20.
3.1 Selection criteria
3.1.1 Environmental stressors
We aimed to study the burden of disease in the general population associated with stressors in the physical 
environment. Occupational hazards and risks associated with lifestyles (e.g. alcohol use, active smoking, 
nutrition), as well as infectious diseases, were excluded from the assessment.
Four criteria were defined for selection of environmental stressors to be included in the study: 
• Public health impact; 
•	 High individual risk; 
•	 High political or public concern;
•	 Economic significance.
In addition, the selection was affected by the feasibility of the calculation. Therefore, we also considered:
•	 availability of exposure data
•	 availability of evidence-based exposure response function(s)
•	 availability of baseline health statistics.
Discussion among environmental health experts as represented in the EBoDE working group selected the 
environmental stressors based on these selection criteria.  A first list of stressors was divided into two parts: 
•	 a high priority list of stressors, which either scored high on many of the criteria and/or which were 
relatively easy to calculate
•	 a medium priority list of stressors.
High priority list of environmental stressors Medium priority list of environmental stressors:
Benzene
Dioxins (including furans and dioxin like PCBs)
Second-hand smoke (SHS)
Formaldehyde
Lead
Transport noise
Ozone
Particulate matter
Radon
1,2-Dichloroethane
Accidents - domestic
Accidents - traffic
Acrylamide
Arsenic
Chlorination by-products
Carbon monoxide (CO)
Damp housing
Foodborn epidemics
Indoor insecticides
Methyl mercury 
UV radiation
Waterborne epidemics
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The pilot project, which is described in this report, only included the stressors on the high priority list. 
These stressors will be shortly introduced in paragraphs 3.2 to 3.10. This list represents only a limited 
number of environmental stressors, and therefore the results of this study cannot be interpreted as 
estimates of the complete environmental portion of the total burden of disease. 
The stressors on the medium priority list are candidates for addressing in subsequent studies.
3.1.2 Health outcomes
For every environmental factor, a set of health endpoints had to be selected which are causally linked to the 
exposure of interest. Only health effects that are included in the International Statistical Classification of 
Diseases and Related Health Problems (ICD) were selected. Therefore, wellbeing effects and for example 
‘noise annoyance’ were not included. 
Within that definition of health, the health endpoints were selected based on the following criteria:
• “sufficient” evidence for a causal relationship between exposure to the environmental stressor and the 
health effect
•	 “sufficient” evidence that the health effect is substantive enough to have an impact on the burden of 
disease estimate
•	 sufficient data to carry out the calculations (burden of disease data, exposure-response functions).
For some stressors, the exclusion of health endpoints with insufficient evidence may have led to 
underestimation of the results, for example for lead and dioxins. On the other hand for dioxins the 
selection of total cancer as the modelled health endpoint and assuming all cancer cases lethal may lead 
to overestimation (see also chapters about the individual stressors and the discussion on uncertainty in 
Chapter 5).
The health endpoints considered in this project and the corresponding exposure-response functions 
are summarized in Table 3-19 in section 3.12. 
3.1.3 Exposure-response functions
For each combination of environmental stressors and health endpoints, exposure-response functions were 
selected from:
•	 International recent meta-analyses or WHO guidelines
•	 If not available: individual high quality studies
3.1.4 Exposure data
Exposure data were as much as possible collected from international harmonized and validated sources. 
If such data were not available, national data sources were used. In such cases, national data needed to 
characterize the population exposures in a representative and comparable manner, accounting for potential 
differences in the urban and rural exposures, different age groups, gender and other relevant sub-groups.
International exposure data were used for SHS, transport noise, ozone, PM and radon. National data 
were used for benzene, dioxins, formaldehyde and lead, with complementary information from (non-
comprehensive) international data sources used when available (AirBase ambient data for benzene; several 
international multicenter studies for indoor concentrations of benzene and formaldehyde covering some 
of the participating countries, and WHO Mother’s milk database for dioxins). The sources of exposure 
data are summarized in Table 3-20 in section 3.12. Exposure data for the target year 2004 are presented in 
Table 3-21 in the same paragraph. 
The exposure trends for the year 2010 were estimated using existing data and author judgment to 
facilitate the evaluation existing policies in the light of the impact estimates for 2004. For several stressors 
(e.g. lead, dioxins) not enough data were available to make sensible trend estimates. For other stressors 
(PM, ozone, benzene), temporal and/or spatial variability was so large that reliable evaluations of the 
trends on the basis of these data were not possible. In these cases, expert judgment was used to estimate 
trends and corresponding confidence intervals. The estimated trends are summarized in Table 4-4. Due to 
the large uncertainties no national trend estimates were created. 
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3.2 Benzene
3.2.1 About benzene
Benzene is an organic chemical compound that was added to gasoline in the past. The use of benzene as an 
additive in gasoline is now limited, but it is still used by industry in the production of for example drugs 
and plastics. In addition, cigarette smoke contains some benzene. 
Inhalation is the major route of human exposure to benzene. However, exposure may also occur 
through oral absorption or by dermal exposure (primarily in workplace settings). Exposure to benzene-
contaminated water can cause inhalation and dermal absorption in the general population (e.g. when 
having a shower), but this does not occur often (US Department of Health, 2007).
The genotoxicity of benzene has been extensively studied. Benzene is a known carcinogen for which no 
safe level of exposure can be recommended. The most significant adverse effects from prolonged exposure 
to benzene are haematotoxicity, genotoxicity and carcinogenicity (IARC group 1 carcinogen) (IARC 1982, 
1987). Chronic benzene exposure can result in bone marrow depression expressed as leukopenia, anaemia 
and/or thrombocytopenia, which can in turn lead to pancytopenia and aplastic anaemia (WHO, 2000b). 
Increased mortality from leukaemia has repeatedly been demonstrated in workers occupationally exposed 
(Arp et al 1983, IARC 1982, Decouflé et al 1983, Bond et al 1986, McCraw, 1985, Yin 1987, Paxton et al. 
1994a, b). There are also studies that using proxies of benzene exposure indicate an increased risk of 
leukaemia in children, but conclusions are not definitive (Weng et al, 2009, Brosselin et al, 2009, Whitworth 
et al 2008, Gunier et al 2008, Steffen et al, 2004, Crosignani et al, 2004, Pearson et al, 2000, Nordlinder et 
al, 1997).
Benzene was selected in the EBoDE project because it may pose high individual risks and is still 
of global concern. Even though policies in Europe have already greatly reduced environmental benzene 
exposure, it is still identified as a concern (e.g. the INDEX project identified benzene as high priority 
stressor (Koistinen et al., 2008, Kotzias et al., 2005); European air quality directive 2008/50/EC; setting of 
WHO guidelines for indoor air quality (WHO, 2010b)).
3.2.2 Selected health endpoints and exposure-response functions
Benzene effects were estimated for leukaemia, including morbidity and mortality. Other proposed health 
endpoints were not included, because they only occur at high exposure levels, typical of occupational 
settings. We used the exposure response function as recommended by the WHO Air Quality Guidelines 
(WHO, 2000b) (see Table 3-19 in section 3.12). WHO uses the 1984 risk calculation of Crump (1984), 
in which the geometric mean of the range of estimates of the excess lifetime risk of leukaemia at an air 
concentration of 1 µg/m3 is estimated to be 6 × 10-6 (unit risk). This estimate falls within the range of the 
risk estimate that is used by the US EPA (2.2 x 10-6 to 7.8 x 10-6 per µg m-3). This unit risk is applied to the 
whole population, including children. Specific estimates that have been supplied for children could not be 
used, because the underlying studies often use proxies of exposure (petrol station density, traffic density, 
etc.) instead of actual benzene exposure levels. 
The estimated number of leukaemia cases were used to calculate the population attributable fraction 
using method 2A.
3.2.3 Exposure data
Benzene exposures are best described by residential indoor air levels (µg m-3). Besides being affected by 
benzene levels in outdoor air, indoor levels may be raised especially by indoor smoking and potentially the 
storage and use of fuels e.g. in case of attached garages and storage rooms.
Benzene is a regulated ambient pollutant and therefore outdoor monitoring is required by the 
European Union. Benzene measurements are included in the AirBase database (European Environment 
Agency, AirBase, 2009).
Benzene exposure is estimated from national indoor levels, supplemented with outdoor levels. 
Different national data demonstrate that benzene exposure concentrations vary from 0.9 µg m-3 in the 
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Netherlands to 2.9 µg m-3 in Italy. The data used in this project are summarized in Table 3-21 in section 
3.12.
The confidence levels of the exposure data cannot be directly compared, because the measurements 
are based on different time periods. Data from the Netherlands and France reflect a 1 week average 
exposure, while Italian and Finnish data are based on 2 day measurements. 
Sources of uncertainty in exposure data include differences in sampling selection. In France, data 
reflect a large number of dwellings, while in other countries data are limited to a smaller number of 
monitored houses. In addition, the presence or absence of tobacco smoke in indoor environments is 
not always reported, making comparison more difficult. This at least partly explains the higher levels in 
Finland, where benzene from smoking was included. In Italy, levels are likely to be higher because of the 
large number of two-stroke engines used there, which emit a lot of benzene. 
TABLE 3-1. Characteristics of benzene indoor concentration measurements.
Country Including benzene from 
smoking
Sample size Time period of 
measurements
Belgium Yes 85 houses and 25 day-care 
centres
Finland Yes random; 20 adults 2 day average
France Yes 567 residences 1 week average 
Germany Yes 1790 subjects
Italy Yes 50 subjects 2 day average
Netherlands Yes 1240 dwellings 1 week average 
3.3 Dioxins (including furans and dioxin-like PCBs)
3.3.1 About dioxins (including furans and dioxin-like PCBs)
Dioxins (including furans and dioxin-like PCBs) are a group of polychlorinated organic compounds with 
the same toxic mechanism. They are by-products of various industrial processes and combustion activities 
and are considered to be highly toxic. 
Dioxins and dioxin-like PCBs are quantified by toxic equivalents (TEQs) representing the total 
toxicity compared to the most toxic compound, 2,3,7,8-Tetrachlorodibenzodioxin (TCDD). The power 
of toxicity is calculated with Toxic Equivalent Factors (TEFs), which allow the toxic potentials of each 
compound to be added up, in order to derive the TEQ of the mixture. Acute toxicity, leading for example 
to chlorakne or alteration of liver function, is only expected at very high doses. Long-term exposure to 
dioxins has been linked to effects on the immune system, the nervous system, the endocrine system and 
reproductive functions and is also known to cause tooth and bone defects, diabetes as well as several types 
of cancer (USEPA, 2003). The association between dioxins and cancer has been most consistent for non-
Hodgkin’s lymphoma. IARC classified TCDD (2,3,7,8-Tetrachlorodibenzo-p-dioxin), as a “known human 
carcinogen” (IARC, 1997). All other dioxin-like compounds are classified as “likely to be carcinogenic to 
humans”.
This group of chemicals is selected in EBoDE because of their high toxicity and potential troubling 
exposures through e.g. mothers milk.
3.3.2 Selected health endpoints and exposure-response functions
In EBoDE, we have quantified the effect of exposure to dioxins and dioxin-like PCBs on cancer (all cancer 
types, mortality only). The non-fatal and non-cancer effects were not suited for health impact assessments 
due to difficulties in estimating the exposure-response relationships and the other input parameters 
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necessary for estimating DALYs. Therefore, our estimates may underestimate the true dioxin-related 
burden of disease. 
Leino et al. (2008) assumed a linear exposure-response relationship for excess cancers associated with 
dioxin intake. They estimated the health risk for toxicity equivalent intake assuming additivity of the 
toxicity of the different types of dioxins and all cancer cases to be lethal. 
The EBoDE calculations use the Leino et al. (2008) approach, but the results have been corrected with 
an updated cancer slope factor 1×10-3 per pg/kg/d of dioxin intake of the U.S. Environmental Protection 
Agency (USEPA, 2003; NAS, 2006). The assumption that all cancers are lethal may lead to overestimation 
of the impacts. 
The health endpoints considered in this project for dioxins and the corresponding exposure-response 
functions are summarized in Table 3-19 in section 3.12. YLD estimates in the table are based on the 
attributable fraction derived from the ERF using method 2A (see Figure 2-1), which is applied to the total 
YLD for all cancers as represented in the WHO database.
3.3.3 Exposure data
Dioxins and dioxin-like PCBs are persistent and bio-accumulating. The main exposure route for these 
chemicals is animal fat in nutrition, which accounts for about 90% of all exposure. Other routes, such as 
inhalation, play a minor role. 
In order to estimate health effects related to dioxin exposure, daily intake data were needed. This 
intake depends on eating habits, age, gender, body weight and food consumption. Often, breast feeding 
contributes to the highest intake of dioxins for humans in their life. Dioxins have a long half life. Therefore 
the development of health effects in humans depends not only on the daily intake, but also on the body 
burden accumulated over years. On average, the daily intake of dioxins and dioxin-like PCBs decreases, 
while the body burden increases with age. 
The cancer slope factor is expressed for daily intake of adults. There are different ways to measure the 
daily intake, each with different limitations. Table 3-2 describes some different measurement methods and 
provides short information about their use and limitations. 
TABLE 3-2. Different ways to measure daily intake of dioxins and dioxin-like PCBs.
Type of measurement Type of use Specific limitations and uncertainties
A Survey (questionnaire) 
on food consumption
Information on food consumption 
and about the content of dioxins in 
representative food samples allow 
modelling of daily intake 
Results are modelled for an average 
population - food contamination and 
eating habits can differ on a large scale
B Total diet studies The total diet in a population group 
over a certain time period and dioxin 
in this food or representative food 
samples are measured. 
Results are only relevant for the 
investigated groups and not necessarily 
representative for the whole 
population, sampling period influence 
the results.
C Human biomonitoring 
Investigation of human 
milk or blood levels
Analyses of samples can show the body 
burden. Experimental scaling is used to 
convert observed biomonitoring results 
(blood) into daily intakes.
D-R function is based on daily intake. 
Human milk or blood samples are not 
widely available. 
Different fat content of the bodies 
influences the results.
In addition, in all these studies different compounds can be measured: 
(i) Only dioxins and furans; 
(ii) dioxins, furans; and dioxin-like PCBs
(iii) dioxins, furans and dioxin-like PCBs as well as all other dioxin-like compounds detected as dioxin-
like activity, expressed as TEQ in Bioassays (e.g. CALLUX). 
In the EBoDE project, we have used national exposure data because there is no international comparable 
data source available. The different countries have used different methods to derive the daily intake values. 
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Table 3-3 provides a summary of the data and sources for dioxin. The specific data used in this project are 
summarized in Table 3-21 in section 3.12.
For the EBoDE project daily intake data are expressed as Toxic Equivalent (TEQ), estimated using the 
Toxic Equivalent Factors (TEFs) as provided by WHO (Van den Berg et al. 1998). Even though later TEFs 
exist (Van den Berg et al., 2006; http://www.who.int/ipcs/assessment/tef_update/en/), we used the results 
of the 1998 review, because most available data have been calculated using these TEFs. 
TABLE 3-3.: Summary of the sources of dioxin data. Explanation for A, B C see Table 3-2.
Countries Population 
groups
Source
 
 
Sampling
years
Compounds
measured
Dioxin intake
2004
pg/kg bw/d
Belgium (A) female 18-44 y
adults 50-65 y
adults
Bilau 2008
Bilau 2008
Calculated mean
2002–2006 Calux-all dioxin-
like compounds1
2.1
1.7
1.9 (mean)
Finland (A) all Kiviranta et al 2005 2002 Dioxins+PCB 1.5
France (C) 30–65 y Fréry et al. 2006 2004 Dioxins+PCB 2.32
Germany (A) adults Umweltbundesamt 
2005
2003 Dioxins+PCB 2.0
Italy (A) 13–94 y Fattore et al 2006 1997–2003 Dioxins+PCB 2.3³
Netherlands 
(A+B)
adults De Mul 2008 2004 Dioxins+PCB 1.04
¹ Belgium – Dioxin and all dioxin-like compounds are measured with Bioassay, only the sum of all dioxin-like compounds is given; the daily 
intake was calculated as mean of the 2 adult groups.
² France – daily intake calculated based on blood concentration of 27.7 WHO-TEQ pg/g blood fat.
3 Italy – daily intake were calculated using, for most dioxin and DL-PCB concentration data, a database available from the European 
Commission (Gallani et al., 2004).
4 Netherlands – Values in the study were calculated using TEFs from 2005. For comparability, we have adjusted the values as presented by 
Mul et al (2008) by adapting the results to TEF 1998 adding 10%.
We have only used data on the daily intake of adults. We have chosen to do so, because the daily intake 
differs substantially between different age groups. The highest intakes are calculated for breastfed babies 
(about 50 to 100 WHO-TEQ pg/kg bw/d). Children have a higher intake than adults because of the 
different proportion between body weight and food intake and their different food habits (children take 
more milk and dairy products). Since there are only very few data for children available, we have limited 
ourselves to adults.
Due to the differences in measurement approach, it is difficult to compare dioxin intake numbers 
between countries. As a form of quality assurance, we have compared our daily intake estimates of dioxins 
and dioxin-like PCBs to international data on dioxins and PCBs in mother's milk (milk data from 2001–
2003) as provided by WHO in the ENHIS-database (WHO, 2007a) and from Malisch and Leeuwen (2003). 
In principle, the ratio between the estimated daily intakes and the levels of mother’s milk should be roughly 
similar between countries. The ratios are presented in Table 3-4. As can be seen from this table, the ratios 
are relatively similar across the countries, except in the Netherlands, where the intake level seems to be 
somewhat lower than in the other countries in comparison with the mother’s milk levels. We have not 
corrected for this difference in the EBoDE calculations, as the causes for the difference are yet unknown. 
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TABLE 3-4. Comparison of dioxins and PCBs human milk (WHO, 2007a) and the estimated daily intakes (country-
specific results – see Table 3-3.
 Countrya)
 
Human milk
ng TEQ/kg fat
Daily intake
pg TEQ/kg bw/d
Factor
milk/intake
Belgium 29.5 1.9 16
Finland 15.3 1.5 10
Germany 26.2 2.0 13
Italy 29.0 2.3 13
Netherlands 29.8 1.0 30
a) France was not included in the WHO-milk study.
3.4 Second-hand smoke
3.4.1 About second-hand smoke
Second-hand smoke (SHS; also called environmental tobacco smoke or passive smoking) is a known 
human carcinogen (IARC, 2004). Exposure to SHS has been shown to cause lung cancer, IHD (ischemic 
heart disease) sudden infant death syndrome, asthma, lower respiratory infections in young children, 
low birth weight, reduced pulmonary function among children, acute otitis media, and acute irritant 
symptoms (WHO, 1999; Californian EPA 2005; US Surgeon General 2006; IARC 2004, Jaakkola et al. 
2003). Most evidence for SHS-related impacts is fairly consistent. 
SHS has been selected in our study because of its high public health impact, public concern and 
political interest. Policy measures to (further) reduce SHS exposure have been implemented in the recent 
past (e.g. the smoking ban) and further policy actions may be taken in the future. 
3.4.2 Selected health endpoints and exposure-response functions
Out of the large number of health endpoints that SHS is associated with, we selected mortality and 
morbidity due to lung cancer and ischemic heart disease (IHD), morbidity due to onset of asthma (both in 
children and in adults), lower respiratory infections and acute otitis media. For the other health endpoints 
mentioned above, strong evidence is available, but the necessary disease statistics were lacking.
For the SHS-related burden of disease calculations, we have followed the recent WHO methods on 
the global estimation of disease burden from SHS (Öberg et al. 2010). A summary of outcomes with their 
respective evidence levels is provided in Table 3-5. The exposure response functions are presented in Table 
3-19.
The selected exposure-response values are not gender-specific (e.g. exposure to male or female 
smoking spouse; exposure to paternal or maternal smoking). Instead, we used the mean relative risk for 
exposure to adults’ smoking. This choice was made in order to limit the sensitivity to gender-specific 
changes in smoking habits over time and across countries, and because not all exposure data were provided 
separately for men and women.
The selected outcomes are being applied only to non-smokers, i.e. to the non-smoking disease burden. 
To that effect, the disease burden due to active smoking has been deduced from the total disease burden, by 
country (based on total disease burden and active smoking disease burden by country provided by WHO; 
update 2002 based on Ezzati et al. (2004)).
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TABLE 3-5. Summary of recent reviews of health effects of second hand smoke (Adapted from: Öberg et al. 2010). 
Health endpoint Description Conclusion regarding the level of evidence 
(in 3 reports)
WHO (1999) Californian 
EPA (2005)
U.S:. Surgeon 
General (2006)
Outcomes in children
Acute lower respiratory 
infection (ALRI)
Incidence of acute lower 
respiratory illnesses and 
hospitalisations
*** *** ***
Otitis media (middle ear 
infection)
Incidence of otitis media *** *** ***
Asthma onset Incidence of new cases n *** **
Outcomes in adults
Asthma induction Adult-onset incident asthma *** ** n
Lung cancer Incidence *** *** ***
Ischemic heart disease (IHD) Incidence of any ischemic 
heart disease
*** *** n
* = The evidence of causality is concluded to be “inconclusive”, “little”, “unclear” or “inadequate”.
** = The evidence of causality is concluded to be “suggestive”, “some” or “may contribute”.
*** = The evidence of causality is concluded to be “sufficient” or “supportive”.
n = Not evaluated in the report.
3.4.3 Exposure data
Exposures to SHS and background risks vary by gender. Therefore, the data collection should account for 
differences in the exposures by gender. Some health effects are specific for children, so exposure data also 
had to be collected separately for children. Overall, the following exposure data are required for estimating 
the health impacts from SHS:
1. Percentage of children exposed to SHS (i.e. regularly exposed), OR percentage of children having at 
least one smoking parent
2. Percentage of non-smoking men exposed to SHS
3. Percentage of non-smoking women exposed to SHS
For exposure data collection, we used data from national and international surveys as for example the 
Survey on Tobacco by the Gallup Organization for the European Commission (EC, 2009) or the European 
Community Respiratory Health Survey (Janson et al. 2006). The fieldwork for this study was conducted 
in December 2008 and over 26,500 randomly-selected citizens aged 15 years and over were interviewed 
in the 27 EU Member States and in Norway. The exposures for the six countries included in EBoDE 
are presented in Table 3-6. The “upper estimate” is used as the most realistic estimate, as this exposure 
description matches best the exposure definition used in epidemiological studies from which we derived 
our exposure-response functions. The lower estimates are provided in Table 3-6 for future sensitivity 
analysis. Table 3-21 in section 3.12 provides a summary of these data.
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TABLE 3-6. Summary of European SHS exposure data for children and non-smoking adults.
Children Adults
[%] Data year, 
reference
men [ %] women 
[%]
total
[%]
Data year, reference
Belgiuma) - - 59
34
-
48
32
-
53
33
25/30b)
1990–1994, ECHRS I1
2002, ECRHS II1
2008, Eurobarometer2c)
Finland 7 1996, Lund3 14
-
-
13
-
-
-
15
6/14b)
2002, Jousilahti4
2004, NPHI5
2008, Eurobarometer2d)
France 23/33b) 2005, INPES6 38
23
-
-
46
30
-
-
42
26
13/21b)
13/22b)
1990–1994, ECHRS I1
2002, ECRHS II1
2005, INPES6b)
2008, Eurobarometer2
Germany 24 2003–2006, 
GerES IV7
48
51
28
-
42
60
26
-
44
-
27
20/28b)
1990–1994, ECHRS I1
1998, BGS8
2002, ECRHS II1
2008, Eurobarometer2
Italy 50 2001, 
ICONA9
62
37
-
49
30
-
55
34
22/26b)
1990–1994, ECHRS I1
2002, ECRHS II1
2008, Eurobarometer2
Netherlands 20/36b) 2000–2005, 
RIVM10e)
68
-
45
-
-
67
-
33
-
-
67
30
39
18/40b)
18/27b)
1990–1994, ECHRS I1
1998–2001, RIVM10
2002, ECRHS II1
2004–2007, RIVM10
2008, Eurobarometer2
NA: Adequate data not available
NB: Additional national data are available for some countries, however, these did not match the description of regular exposure. 
Definitions used for lower and upper estimates: 
a) For Belgium, no data for children was found; estimate is calculated using mean of other countries. 
References: 1 Janson et al. 2006; 2 EC 2009; 3 Lund et al. 1998; 4 Jousilahti and Helakorpi 2002; 5 Finnish National Public Health Institute, 
2004; 6 Institut National de Prévention et d’Education pour la Santé (INPES) 2005; 7 Conrad et al. 2008; 8 Schulze and Lampert 2006; 
9 Tominz et al. 2005; 10 van Gelder et al. 2008.
b) Lower/upper estimates; INPES: Lower estimate based on “regular” exposure; upper estimate based on exposure “from time to time”; 
Eurobarometer: Lower estimate based on daily exposure of more than one hour exposure at work and home exposure; upper estimate 
based on daily exposure of also less than one hour at work and home exposure. RIVM: ranges based on values provided by various studies.
c) Exposure at home and at work supposed to be distributed equally. 
d) Finnish national data (NPHI) also provide survey results, but total exposure to SHS for non-smokers are more difficult to interpret. 
Therefore only the Eurobarometer data were taken into account here.
e) The RIVM report contains data from various studies (e.g. Doetinchem, STIVORO, PIAMA)
Available exposure data (Table 3-6) range across several years, and have been assessed with slightly differing 
definitions of exposures. In order to estimate exposure data for the target year (2004), exposures have been 
modelled on the basis of the survey data listed in Table 3-6 as follows:
• Modelling was performed with total adult data, and men/women and children data were assumed to 
vary according to the same trends.
•	 Power functions showed the highest correlations in most countries, and were therefore applied in all 
countries. No trend was apparent for Finland, therefore only the mean was applied. 
 
Resulting trends are displayed in Figure 3-1, and estimated exposure data for 2004 in Table 3-7.
3   Selected exposures and health effects
34 Report 1/2011
National Institute for Health and Welfare (THL)
European Perspectives on
Environmental Burden of Disease
* A trend line for Finland was not considered sufficiently reliable due to paucity of data showing no apparent trend.
NB: Points correspond to the survey data presented in Table 3-6.
FIGURE 3-2. Observed SHS exposure levels (markers) (% of non-smokers) for adults and corresponding modelled 
trends (lines) in the participating countries.
TABLE 3-7. Modelled exposure to SHS, in children and non-smoking adults in 2004.
Year 2004 Children Adults (total) Women Men
 Lower* 
[%]
Upper* 
[%]
Lower 
[%]
Upper 
[%]
Lower 
[%]
Upper 
[%]
Lower 
[%]
Upper 
[%]
Belgium NA NA 28 32 27 31 29 33
Finland 4 NA 14 14 14 14 14 14
France 23 33 17 25 20 29 15 22
Germany 24 NA 26 31 25 30 27 33
Italy 40 NA 26 30 23 26 29 32
Netherlands 20 36 22 30 19 25 26 34
* Lower and upper estimates correspond to different computations of survey data. For example, the upper estimate corresponds to the 
inclusion of shorter durations of exposure from certain surveys.
3.5 Formaldehyde
3.5.1 About formaldehyde
Formaldehyde is a high-production volume chemical widely used in building materials, industrial 
processes and wide range of products. Formaldehyde is widely present both indoors and outdoors, but it 
reaches high levels mostly indoors. It is used in the production of several building materials and household 
products, or it can be a by-product of combustion. The high volatility of the compound can lead to high 
formaldehyde levels in indoor spaces. 
Predominant acute symptoms of formaldehyde exposure in humans are irritation of the eyes, nose and 
throat and aggravation of asthma symptoms (WHO, 2000a). A number of studies point to formaldehyde 
as an important indoor irritant associated with respiratory illness. A relationship between asthma-like 
symptoms and indoor concentrations of formaldehyde has been reported, as well as between exposure to 
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formaldehyde emitted from indoor paint and asthma. Repeated exposures are not associated with more 
severe effects or lowering of the threshold concentration. Consequently, short-term concentrations are 
predictive of the effects also after long-term exposure. 
Exposure to formaldehyde has also been associated with development of cancer. Convincing evidence 
exists of high concentrations of formaldehyde being capable of inducing nasal cancer in rats and possibly 
in mice and genotoxic effects in a variety of in vitro and in vivo systems. Sinonasal cancer in humans has 
also been associated with high formaldehyde exposures in occupational industrial settings (ranging from 2 
to 6 mg m-3) (WHO, 2000a). Based on this, IARC has recently classified formaldehyde as carcinogen group 
1 (IARC, 2006a).
Formaldehyde was included in EBoDE due to its high toxicological potential, economic significance 
and related political concern.
3.5.2 Selected health endpoints and exposure-response functions
In the EBoDE study, only the development of asthma in toddlers has been included. Sinonasal cancer 
was not included, because the WHO Air Quality Guidelines working group (WHO, 2000a) as well as 
recent update of the reviews for the development of WHO Guidelines for indoor air quality (WHO, 
2010b) concluded that there is no epidemiological or toxicological evidence that formaldehyde would be 
associated with sinonasal cancer at levels below 1 mg/m3. The WHO Guidelines for Indoor Air Quality use 
eye irritation as the main health end-point associated with formaldehyde; however, due to difficulties in 
estimating a burden of disease from irritation this endpoint was not included in our calculations.
Association with asthma is suggested by the systematic review by McGwin et al., 2010, even though 
evidence has not been consistent across all the studies (e.g. Krzyzanowski et al, 1990). We selected childhood 
asthma as the endpoint for formaldehyde, but due to the inconsistencies in the scientific evidence the 
estimates calculated here should be considered preliminary and to be confirmed by future research. In 
order to estimate formaldehyde-related asthma, we used the exposure-response function as reported 
by Rumchev et al. (2002). They studied a cohort of 88 children in Perth, Australia. For every 10 µg m-3 
increase in formaldehyde exposure in bedrooms, they found an increase of 3% in the risk of having asthma 
(OR=1.03, 95% CI 1.02–1.04). Based on a reanalysis of their data over reported exposure categories and 
rescaling for 1 µg m-3, the relative risk used in our calculation is 1.0167 (see also Table 3-19 in section 3.12). 
Asthma effects were calculated for children (<3 years). A similar association may potentially exist for older 
children and adults, but due to the lack of evidence such relationship was not modelled. This may lead to 
underestimation of the true formaldehyde-related burden of disease. 
A threshold level for effects was applied. The original study by Rumchev reported elevated risks 
starting from exposures of 60 µg m-3. When their data were plotted in order to derive the relative risk, the 
threshold could be even as low as 40 µg m-3. However, the Rumchev study was criticized for confounding 
factors. WHO (2000a, 2010b) indicated that the lowest concentration that has been associated with 
nose and throat irritation in exposed workers after short-term exposure is 0.1 mg m-3, although some 
individuals can sense the presence of formaldehyde at lower concentrations. To prevent significant sensory 
irritation in the general population, an air quality guideline value of 0.1 mg m-3 as a 30-minute average 
was recommended as the WHO Guideline (WHO, 2010b). This is the threshold value that we used in 
our calculations. Since this is an order of magnitude lower than the presumed threshold for cytotoxic 
damage to the nasal mucosa, there is a negligible risk of upper respiratory tract cancer in humans below 
this threshold. As part of the uncertainty analysis, we compared alternative threshold models for cancer 
(threshold levels of 40, 60 and 100 µg m-3) and asthma, see section 5.2.
3.5.3 Exposure data
Inhalation is the dominant pathway for formaldehyde exposure in humans. The relevant exposure metric 
is the residential indoor air level (µg/m-3). As indicated above, both of the exposure-response models used 
apply a threshold level (100 µg m-3). Therefore, it is necessary to assess the fraction of the population being 
exposed to levels higher than this threshold level. A probabilistic simulation model was used to calculate the 
fraction of the population exceeding the threshold using mean and standard deviation data and assuming 
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lognormal distributions. No international exposure data sources were identified for formaldehyde, so data 
have been collected from heterogeneous national sources. 
For Belgium, Germany and the Netherlands, only mean exposures were available, without information 
about the variability. For these three countries, the exposure distributions were based on the data from the 
other countries (estimated coefficient of variation: 0.6). 
TABLE 3-8. Population distributions of residential formaldehyde concentrations.
Country mean
µg m-3
sd
µg m-3
References
Belgium 24.0 14.4¹ Swaans et al,. 2008
Finland 41.6 22.4 Jurvelin et al, 2001
France 23.0 14.0 OQAI, 2006
Germany 26.0 15.6¹ Umweltbundesamt, 2008
Italy 16.0 8.0 Lovreglio et al, 2009
Netherlands 13.0 7.8¹ Dongen,van & Vos, 2008
¹ Mean coefficient of variation of the countries with data on variability used for estimation.
Exposure data for formaldehyde are presented in Table 3-21 in section 3.12.
The mean formaldehyde indoor concentrations vary from 13 µg m-3 in the Netherlands to about 
42 µg m-3 in Finland. In Finland formaldehyde exposure levels are higher than in many other developed 
countries due to the construction materials used and the relatively tightly sealed building envelopes. As 
shown in Figure 3-3, approximately 42% of population is exposed to levels above 40 µg m-3 and 2 % above 
100 µg m-3.
FIGURE 3-3. Estimated formaldehyde exposure distribution in Finland.
Data comparability is compromised for formaldehyde by the differences in population sampling. In 
France, Germany and the Netherlands, data measurements are representative for country-wide exposure. 
However, in other countries, measurements have only been carried out in a few cities or were based on a 
smaller subset of houses. 
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3.6 Lead
3.6.1 About lead
Lead is present in the environment due to former application of lead in gasoline, leaded drinking water 
pipes, and use of lead in paints and other housing materials. Exposures to lead originate from various 
sources including air, drinking water, food stuff as well as surfaces and consumer products. 
Lead is one of the most studied environmental pollutants and has been associated with a large 
number of health implications (WHO, 2007b). Exposure to lead may cause, amongst other things, kidney 
damage, miscarriages, effects of the nervous system, declined fertility, alterations in growth and endocrine 
function, and behavioural disruptions (Hauser et al. 2008; Lanphear et al., 2005; Selevan et al. 2003). Lead 
is a known neurotoxic pollutant affecting the development of the central nervous system of children and 
consequently their intelligence. Effects on attention, behaviour disorders and hearing-threshold changes 
have been described as particularly important (Needleman 1990, WHO/IPCS 1995). Lead exposures have 
also been shown to be associated with increased blood pressure and risk of hypertension in (female) 
adults (Nash et al. 2003). Correlations with low lead levels have been reported for the attention deficit 
hyperactivity disorder (ADHD) (Braun et al., 2006). In addition, there is evidence showing that lead may 
cause cancer. Lead has been loosely linked with cancers of the lung and stomach. IARC (2006b) rated lead 
and inorganic lead compounds as probably carcinogenic to humans (Group 2A). Current studies suggest 
that there is no “safe” level of lead exposure.
Most of the health endpoints are significant at much higher exposure levels that are found in European 
population today. Exposure to lead has significantly decreased for many countries in the last two decades, 
especially since the phasing out of leaded gasoline and the replacement of leaded water pipes. For example, 
Figure 3-3 shows the reduction of internal exposure to lead in humans in German students between the 
1980s and now (German Environmental Specimen Bank [Umweltprobenbank des Bundes], data available 
online at www.umweltprobenbank.de). Indeed, lead has been the success story in environmental policies, 
but the follow-up in exposure data in the general population is poor. 
FIGURE 3-4. Blood-Pb in German Students (1981–2009, geometric mean in µg/l, sampling location: city of Münster) 
(data available at www.umweltprobenbank.de).
3.6.2 Selected health endpoints and exposure-response functions
The EBoDE project focuses on two endpoints that have been shown to be relevant at current exposure 
levels: mild mental retardation (due to IQ loss) and hypertensive disease (due to rise in systolic blood 
pressure). For the other health endpoints, i. a., no empirically sound exposure-response-relationships are 
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available. Therefore, our results may underestimate the actual EBD of lead exposure in Europe. The extent 
of this underestimation cannot be quantified sufficiently. 
The hypothesis of an effect threshold was rejected in several studies (Téllez-Rojo et al. 2006, Binns 
et al. 2007, Chiodo et al. 2004, Kordas et al. 2006). There is strong evidence for an association between 
B-Pb (blood lead) and negative effects on neuropsychological parameters at levels lower than 100 µg/l 
(Walkowiak et al., 1998; Canfield et al., 2004; Carta et al., 2005). Therefore, extending the dose-response 
curve to the range below 100 µg/l is possible. Lanphear et al. (2005) proposed a log-linear model for this 
curve.
Findings on lead’s effects on the central nervous system in the low-dose range are available from 
longitudinal and cross-sectional studies (Lanphear et al., 2005). These studies showed B-Pb and decrease 
in IQ points with B-Pb in children. The WHO model for IQ loss was recently updated to consider B-Pb 
levels above 24 µg/l. It has to be taken into account, however, that no threshold for mental retardation has 
been confirmed, yet. The exposure/response-function (ERF) in the WHO model is:
          (Lanphear et al., 2005; see also Table 3-19 in section 3.12). 
The population distribution of IQ is as defined as N(100;15). When the IQ falls below a diagnostic 
threshold, IQ loss is defined as mild mental retardation, which is the health endpoint used in this study. 
This threshold is set at 70 IQ points. We calculate the number of cases of mild mental retardation by 
estimating how many individuals in the target age group (children 0-4 years) exceed the diagnostic 
thresholds due to the lead exposure.
Several longitudinal studies have examined associations of blood pressure change or hypertension 
incidence in relation to lead concentration in blood or bone. Glenn et al. (2006) concluded that systolic 
blood pressure is associated both with acute changes in the blood lead level as well as with long-term 
cumulative exposure. Blood lead levels can increase in women over the menopause, as lead is released from 
bone. This may increase women’s risk of high blood pressure.
The current WHO model for increased systolic blood pressure in adults aged 20–79 years assumes a 
linear relationship between 50-200 µg/l (increase of 1.25 mmHg for males and 0.8 mmHg for females per 
increase of 50 µg/l B-Pb). Above 200 µg/l, an increase of 3.75 mmHg for males and 2.4 mmHg for females 
per increase of 50 µg/l B-Pb is assumed. The model does not account for aggravating effects of increased 
blood lead levels during the menopause. 
The ERF for mean increase in the systolic blood (mmHg) in the WHO model is (B-Pb >50 µg/l) 
(Fewtrell et al, 2003):
The calculation of the numbers of cases of hypertensive disease is similar to the calculations for mild 
mental retardation. The population distribution of systolic blood pressure is defined as N(135, 15). When 
exposure exceeds the diagnostic threshold, of 140 mmHg, the increase in blood pressure is defined as 
hypertensive disease. We calculate how many individuals in the target age group (>15 year olds) exceed the 
diagnostic threshold due to the lead exposure.
3.6.3 Exposure data
It is not easy to estimate lead exposure levels, because population exposure measurements are not regularly 
conducted, and because of the decreasing trends in lead concentrations which are not fully known. The 
most reliable way to account for all different possible exposure routes is to measure the body burden of 
lead. The commonly used exposure metric for such measurement is the blood lead level (B-Pb, whole 
blood, µg/l).
For the application of the WHO model for IQ loss, distributions of B-Pb (defined by percentiles) are 
necessary, stratified by specific age groups. This means that data are needed about different fractions of the 
population that are exposed to certain categories of B-Pb levels. No coherent international data sources 
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were identified for lead. Hence, data from individual studies conducted in all participating countries were 
used. The year in which these studies were conducted differs between countries and in some cases the 
limited temporal coverage prohibited trend estimation. In these  cases the most recent data have been used. 
It is clear that the limited temporal representativity of the lead exposure data poses a significant source 
of uncertainty. Due to well established lowering trends for lead this is expected to cause mainly unknown 
overestimation of exposures and effects.
The data are presented in Table 3-9 below and summarized in Table 3-21 in section 3.12. As shown in 
Table 3-9, lead data have been measured in different age groups in the different countries. Data from the 
German Environmental Survey (GerES) show that age is an important influencing factor for B-Pb levels 
in humans. As there is virtually no evidence for a significant reduction in B-Pb levels since the year 2000, 
the difference in age groups is assumed to be one of the most important sources of uncertainties when 
comparing the different countries. Unfortunately, B-Pb data are not sufficient to correct the country data 
for age. 
TABLE 3-9. Lead data (µg/l) for different countries, measured in different age groups and years, used in the lognormal 
simulation to yield the required distributional parameters.
Country
Estimates (2004)
Age group Year
AM GM SD
Belgium 22 16 14–15 2000–06
Finland 16 11 Adults 2004
France 26 18 18–74 2006–07
Germany 22 16 20–29 2004
Italy 39 24 18–64 2000
Netherlands 19 11 1–6 2005
AM: Arithmetic Mean; GM: Geometrical Mean; SD: Standard Deviation (estimated using coefficient of variation).
As indicated above, both of the exposure-response models used apply a threshold level (50 µg l-1 and 
24 µg l-1). Therefore, it is necessary to assess the fraction of the population being exposed to levels higher 
than these threshold levels. A probabilistic simulation model was used to calculate the fraction of the 
population exceeding the threshold using mean and standard deviation data and assuming lognormal 
distributions. Standard deviations were estimated for the simulation using a coefficient of variation 
estimated from the Finnish data.
TABLE 3-10. Population distributions of blood lead levels used in the simulation of threshold exeedances assuming 
log-normal distribution.
Country BE FI FR DE IT NL
Adults mean 22.0 16.0 25.0 22.0 39.0 19.0
SD 15.6 11.4 17.8 15.6 27.7 13.5
CV 0.71 0.71 0.71 0.71 0.71 0.71
Children mean 22.0 16.0 25.0 22.0 39.0 19.0
SD 15.6 11.4 17.8 15.6 27.7 13.5
CV 0.71 0.71 0.71 0.71 0.71 0.71
SD: Standard deviation, CV: coefficient of variation.
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3.7 Transport noise
3.7.1 About transport noise
Noise from road, rail, and air traffic affects a great number of people. Exposure to transport noise may 
cause sleep disturbance as well as annoyance, potentially leading to high blood pressure and increased 
incidence of myocardial infarction (WHO, 2000b; Miedema & Vos 2007; Babisch 2006, 2008). Transport 
noise exposure as a part of total environmental noise has also been linked to effects on cognition. Transport 
noise is selected in this study due to its ubiquity and high public health impact. In addition, due to the 
economic significance of transport, noise levels despite technological progress keep on increasing over 
time.
3.7.2 Selected health endpoints and exposure-response functions
As health end-points, high sleep disturbance and Ischemic Heart Disease (IHD) were included (Miedema 
& Vos, 2007; Babisch 2006, 2008). Hypertension and related heart disease due to aircraft noise was not 
considered because no clear review could be identified. Nevertheless, since causal relationships are very 
likely and have been reported recently, this health effect may be considered in the near future (Babisch & 
Kamp, 2009). For railway noise no significant associations with hypertension and IHD could be identified 
(Barregard et al., 2009). 
Effects on cognition were also excluded, as these are difficult to quantify. In addition, severe 
annoyance, as annoyance was not included as annoyance does not fall weithin our definition of health and 
not considered a health effect by, amongst others, WHO. Some other studies (e.g. Knol & Staatsen, 2005) 
have applied a broader definition of health, in which annoyance was included as a health effect because 
it reduces quality of life. These studies show a substantial burden of disease due to transport noise related 
annoyance. 
The formulas applied to estimate transport noise related high sleep disturbance (HSD) are as follows. 
The results directly give the number of people severely sleep disturbed at a certain decibel level for each 
noise source (Miedema et al., 2002, Miedema & Vos, 2007):
Road traffic noise: %HSD = 20.8 - 1.05L
night
+ 0.01486(L
night
)2 
Railway traffic noise: %HSD = 11.3 - 0.55L
night
+ 0.00759 (L
night
)2
Aircraft noise: %HSD = 18.147 - 0.956L
night
+ 0.01482(L
night
)2
L
night
 is a measure of night-time noise, defined as the yearly average of night noise levels (23–7h) at the 
façade of houses. The formulas can be applied in the range of L
night
 from 45 to 65 (max. 70) dB(A) (data 
are regularly available for >50dB(A)).
There is no exclusive causal mechanism postulated specifically to myocardial infarction (MI). 
Therefore, the OR for MI has been applied to all types of ischemic heart disease (Babisch, 2008) according 
to the following formula (Babisch 2006, 2008): 
OR = 1.63 – 0.000613*(L
day,16h
)2 + 0.00000736*(L
day,16h
)3
L
day, 16h 
is defined as the yearly average of day and evening noise levels (7-23h) and L
day
 as the yearly average 
of day noise levels (7-19h) and L
evening
 as the yearly average of evening noise levels (19–23h). The exposure-
response functions are valid for L
day, 16h 
noise levels ranging from 55 to approximately 80 dB(A). 
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FIGURE 3-4. The exposure-response functions for high sleep disturbance (HSD; blue axis) and ischeamic heart disease 
(red axis) presented in graphical form for road, rail and air traffic noise. The OR for Myocardial Infarction, which we 
applied for all ischeamic heart disease (IHD), is modelled only for road traffic (red curve). (Dotted lines display E-R 
functions outside the range where they are considered valid).
3.7.3 Exposure data
The exposure metric used is the average 24h-noise level day-evening-night (L
den
) and the average 8h-noise 
level during night-time (L
night
) in dB(A), separated for road, aircraft and railway traffic. These indices have 
been suggested by the European Environmental Noise Directive (2002/49/EC, “END”, (EU, 2002). 
From the first phase of END-reporting, carried out in 2007/2008, noise exposure data per 5dB(A) 
categories are now available for most of the EU-countries. These data concern: 
• agglomerations with more than 250 000 inhabitants (separately for road, aircraft and railway traffic);
•	 roads outside agglomerations with more than 6 000 000 vehicles/passages per year;
•	 railways outside agglomerations with more than 60 000 trains/passages per year;
•	 major airports with air traffic higher than 50 000 movements/flights per year (some separated for 
inside and outside agglomerations and total).
These data have been aggregated recently and still are to some extent being processed. So far, they only cover 
a relatively small percentage of the EU population. The data are presented in Table 3-11. The population 
coverage of the data for the countries that have so far been included depends substantially on their 
urbanity, on the administrative prerequisites (e.g. extent of cities) and on the location of country (central 
or in periphery) and resulting transit influences. In consequence, the comparability of the countries is 
limited. Additionally, data for Belgium until April 2010 only included Flanders. For France, only data for 
major agglomerations were included. Only exposure levels above L
night
 50dB (L
den
 55 dB) are reported in 
END data, so there are no data about exposure below those levels in the END database.
For ischemic heart disease, the exposure-response function was calculated for a 16h-daytime level 
(L
day
). As a crude but practical tool for conversion, the following easy formula was used:
Lday,16h = Lden – 2.5 (Babisch, 2008)
Unfortunately, END-reporting of many included countries until April 2010 was only complete for Lden but 
incomplete considering data about Lnight. Therefore adjustments had to be made for calculation of people 
affected by high/severe sleep disturbance. As a crude but practical tool for conversion, the following easy 
formula was used:
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Lden = Lnight + 7.5 (expert judgement after first data-pooling, most valid for road traffic noise in 
agglomerations)
There are large differences concerning these conversion factors, especially for conversion from L
den
 to 
L
night
, for which estimates range from +5 (very urban) up to +11 (including rural areas) (WG-AEN 2006). 
For comparability, 7.5 was chosen as a conservative factor, even though in some cases there might be an 
underestimation of real exposure. 
END-reporting covers 5dB(A)-categories. For modelling purposes, the mid-values of the 5dB(A)-
categories (50–54.9 → 52.5) were inserted in the non-linear polynomials as a feasible simplification. 
TABLE 3-11. Baseline exposures for noise (Environmental Noise Directive reporting data, 2007/2008). 
 Road traffic, agglomerations Raw Lden [dB(A)] data from END-Reporting 1st stage 2007
Countries
Population in 
agglomerations
55-59
dB
60-64
dB
65-69
dB
70-74
dB
>75
dB
Population 
2004
Exposed 
>55 dB
Exposed 
population
Belgium (BE) n/a n/a n/a n/a n/a n/a 10 359 676 n/a n/a
Finland (FI) 559 716 87 249 88 660 46 648 14 860 73 5 231 166 237 490 4.5 %
France (FR) 12 704 947 1 665 222 2 198 662 2 477 022 1 908 546 226 977 60 623 894 8 476 429 14.0 %
Germany (DE) 13 499 029 1 219 623 828 255 652 079 336 339 48 910 82 627 588 3 085 206 3.7 %
Italy (IT) 2 934 473 1 957 800 421 300 151 400 80 000 4 700 58 474 754 2 615 200 4.5 %
Netherlands (NL) 5 002 655 827 900 673 300 344 100 44 500 1 000 16 263 535 1 890 800 11.6 %
Sum 34 700 820 5 757 794 4 210 177 3 671 249 2 384 245 281 660 233 580 613 16 305 125 7.0 %
Road traffic, outside agglom.1
Countries
Road length
km
55-59
dB
60-64
dB
65-69
dB
70-74
dB
>75
dB
Population 
2004
Exposed 
>55 dB
Exposed 
population
Belgium (BE) 2 792 201 300 92 100 83 900 91 900 18 000 10 359 676 487 200 4.7 %
Finland (FI) 647 590 246 81 13 1 5 231 166 931 0.02 %
France (FR) 20 274 1 821 229 866 917 461 855 242 042 126 184 60 623 894 3 518 226 5.8 %
Germany (DE) 17 056 1 858 365 840 909 490 458 239 627 41 814 82 627 588 3 471 173 4.2 %
Italy (IT) 6 324 1 654 840 1 382 550 910 380 370 470 121 100 58 474 754 4 439 340 7.6 %
Netherlands (NL) 3 496 128 600 43 600 13 200 1 900 100 16 263 535 187 400 1.2 %
Sum 50 589 5 664 924 3 226 322 1 959 874 945 952 307 199 233 580 613 12 104 270 5.2 %
Rail traffic, agglomerations Raw Lden [dB(A)] data from END-Reporting 1st stage 2007
Countries
Population in 
agglomerations
55-59
dB
60-64
dB
65-69
dB
70-74
dB
>75
dB
Population 
2004
Exposed 
>55 dB
Exposed 
population
Belgium (BE) n/a n/a n/a n/a n/a n/a 10 359 676 n/a n/a
Finland (FI) 559 716 27 513 25 390 16 669 207 0 5 231 166 69 779 1.3 %
France (FR) 2 698 604 48 000 36 600 14 300 8 800 0 60 623 894 107 700 0.2 %
Germany (DE) 10 752 155 194 617 112 457 71 768 18 422 1 919 82 627 588 399 183 0.5 %
Italy (IT) n/a n/a n/a n/a n/a n/a 58 474 754 n/a n/a
Netherlands (NL) 5 002 655 118 600 60 700 25 000 8 800 1 000 16 263 535 214 100 1.3 %
Sum 19 013 130 388 730 235 147 127 737 36 229 2 919 233 580 613 790 762 0.3 %
Rail traffic, outside agglom.2
Countries
Rail length
km
55-59
dB
60-64
dB
65-69
dB
70-74
dB
>75
dB
Population 
2004
Exposed 
>55 dB
Exposed 
population
Belgium (BE) 461 33 300 19 700 16 100 13 400 3 900 10 359 676 86 400 0.8 %
Finland (FI) 96 255 95 48 5 0 5 231 166 403 0.0 %
France (FR) 1 781 624 242 419 956 250 289 139 459 105 232 60 623 894 1 539 178 2.5 %
Germany (DE) 4 435 831 000 304 200 117 500 57 800 43 000 82 627 588 1 353 500 1.6 %
Italy (IT) 438 89 900 61 900 37 300 33 000 24 800 58 474 754 246 900 0.4 %
Netherlands (NL) 854 134 000 76 500 38 100 12 500 3 000 16 263 535 264 100 1.6 %
Sum 8 065 1 712 697 882 351 459 337 256 164 179 932 233 580 613 3 490 481 1.5 %
Air traffic, large airports Raw Lden [dB(A)] data from END-Reporting 1st stage 2007
Countries
Movements
per year
55-59
dB
60-64
dB
65-69
dB
70-74
dB
>75
dB
Population 
2004
Exposed 
>55 dB
Exposed 
population
Belgium (BE) 253 257 106 698 14 766 1 787 0 0 10 359 676 123 251 1.2 %
Finland (FI) 173 000 57 200 1 700 100 0 0 5 231 166 59 000 1.1 %
France (FR) 1 376 340 107 800 9 000 12 100 0 0 60 623 894 128 900 0.2 %
Germany (DE) 1 862 273 479 500 178 000 25 700 1 700 0 82 627 588 684 900 0.8 %
Italy (IT) 992 506 157 500 49 200 9 800 1 400 200 58 474 754 218 100 0.4 %
Netherlands (NL) 440 153 61 600 6 100 1 200 100 0 16 263 535 69 000 0.4 %
Sum 5 097 529 970 298 258 766 50 687 3 200 200 233 580 613 1 283 151 0.5 %
1 Population living close to roads with more than 6,000,000 vehicles/passages per year
2 Population living close to rails with more than 60,000 trains/passages per year 
Raw Lden [dB(A)] data from END-Reporting 1st stage 2007
Raw Lden [dB(A)] data from END-Reporting 1st stage 2007
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3.8 Ozone
3.8.1 About ozone
Ozone in the lower atmosphere (or tropospheric ozone) is not emitted directly, but is formed in the 
atmosphere in photochemical reactions from anthropogenic and natural emissions of precursor 
components involving mostly volatile organic compounds (VOCs) and nitrogen oxides (mainly NO and 
NO
2
). These substances react to form ozone under the influence of sunlight. Ozone is highly reactive and 
therefore other air pollutants also easily consume the ozone present in the air. Therefore, the highest ozone 
levels are typically found in background regions and levels in urban areas are generally lower than in the 
countryside.
Exposure to ozone can lead to a variety of respiratory health effects, such as coughing, throat irritation 
and reduced lung function. In addition, it can worsen bronchitis, emphysema, and asthma (WHO, 2006a). 
Ozone levels are increasing over time, and are cause for political concern. 
3.8.2 Selected health endpoints and exposure-response functions
For ozone, as well as for PM (see section 3.9), we followed the health impact assessment approach as laid 
out in the Clean Air For Europe (CAFE) project and based on WHO European Centre for Environment and 
Health and CLTRAP Task Force on Health consultations. Health effects that are taken into consideration 
include total non-violent mortality, minor restricted activity days (MRADs), and cough and lower 
respiratory symptoms (LRS) in children aged 5–14 years. The choice of these endpoints was guided by 
Cost Benefit Analysis as carried out in the CAFE project (Hurley et al, 2005, WHO 2008). The health 
endpoints considered and the corresponding exposure-response functions are summarized in Table 3-19 
in section 3.12. 
3.8.3 Exposure data
The exposure metric used for ozone calculations is the sum of ozone maximum 8-h levels above 35 ppb, 
called SOMO35 (WHO, 2008). SOMO35 (expressed in µg m-3 × hours) is the sum of the maximum daily 
8-hour concentrations that are exceeding 35 ppb (70 µg m-3) for each day in the calendar year, i.e. e.g. a 
daily level of 100 µg m-3 would contribute 30 to the SOMO35 calculation. Regardless of the name referring 
to the ppb unit of measurement, the values are expressed as mass concentrations (µg m-3).
For ozone (as well as for PM, see section 3.9), exposures were estimated by the European Topic Centre 
on Air and Climate Change (ETC/ACC) using AirBase data and air quality maps (SOMO35) (de Leeuw 
& Horalek, 2009). The European Environment Agency (EEA) has recently published an evaluation of 
new monitoring-based methods to estimate population weighted spatial distributions of ambient PM and 
ozone levels (EEA, 2009). These methods are based on interpolated maps using 10×10 km spatial resolution 
and using observed concentrations from national monitoring networks as primary data source. These are 
combined with regional chemistry transport modelling (CTM) and other supplemental data sources to 
improve estimates in observation-sparse areas. Maps for rural and urban areas were created separately 
and were subsequently merged. This approach aims to provide an objective method for dealing with the 
differences found between the rural and urban interpolated concentration fields in most areas of Europe 
(EEA, 2009). It is different from the earlier Clean Air for Europe (CAFE) work, which relied on modelling 
as its primary source of information and uses monitoring only to calibrate the European Monitoring 
and Evaluation Programme (EMEP) chemical transportation model. The modelling approach is better 
suitable for prospective scenario analyses, while the monitoring based approach may be considered more 
reliable for retrospective analyses.
The air quality maps were prepared for 2005 with interpolation methodology using co-kriging of 
observed concentrations using additional spatial information (EMEP model results, meteorological data, 
altitude, population density map). The year 2005 instead of 2004 was chosen as the modelling year by EEA 
for practical purposes. Description of the maps is given by Horálek et al (2007) and de Leeuw and Horalek 
(2009). A brief introduction to AirBase and a description of the state of and recent trends in European air 
quality is presented by Mol et al (2009). 
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Population weighted ambient ozone concentrations were calculated using population data for 
year 2005. The population density map (resolution 10x10 km) is based on the detailed population map 
prepared by JRC (reference year 2002, see Horalek et al., 2008 for further description of this dataset). The 
population density map for 2005 is made by scaling the 2002-reference map using the 2005/2002 ratio of 
national population numbers. Within a country the same age distribution is assumed in all grid cells.
Resulting population-weighted ozone exposure values for the participating countries are shown in 
Table 3-12 and are also summarized in Table 3-21 in section 3.12. The geographical distribution of the 
SOMO35 levels in Europe is shown in Figure 3-5.
TABLE 3-12.: National population weighted averages of ambient ozone levels (SOMO35) in 2005 for the six EBoDE 
countries (de Leeuw and Horalek, 2009).
Country SOMO35
(µg m-3)
Belgium 2 787
Germany 4 164
Finland 2 580
France 4 756
Italy 8 134
Netherlands 1 920
FIGURE 3-5. Ozone SOMO35-levels in Europe in 2005 (EEA, 2009).
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3.9 Particulate matter
3.9.1 About particulate matter
Exposure to Particulate matter (PM) has been associated with both respiratory and cardiovascular effects 
and total non-violent mortality (Pope and Dockery, 2006, WHO, 2006a,b) and it is the most thoroughly 
internationally reviewed environmental pollutant during the last decade. PM was selected in EBoDE 
due to its high public health impact, economic significance (industry, transport) and political concern. 
Particulate matter is a complex mixture of components from natural and anthropogenic sources and is 
partly created in chemical and physical processes in the atmosphere from gaseous primary components 
like sulphur dioxide, nitrogen oxides, ammonia, and volatile organic compounds. The health implications 
of the particulate matter components have been extensively studied, but still the most convincing 
epidemiological evidence associates PM
2.5
 mass concentrations with the health impacts (Pope & Dockery, 
2006).
3.9.2 Selected health endpoints and exposure-response functions
For PM (and ozone) we followed the health impact assessment approach as laid out in the Clean Air For 
Europe (CAFE) project and based on WHO European Centre for Environment and Health and CLTRAP 
Task Force on Health consultations (Hurley et al. 2005, WHO, 2006a, b). PM
2.5
 and PM
10 
both serve as 
indicators of a complex mixture of physically and chemically heterogeneous composition. In the EBoDE 
calculations, we calculated burden of disease related both to PM
10
 and to PM
2.5
 exposure. Due to the overlap 
between these two indicators, in the aggregate results only the results for PM
2.5
 are included. For PM
2.5
, we 
calculated the burden of disease for cardiopulmonary mortality, lung cancer mortality, total non-violent 
mortality, chronic bronchitis and restricted activity days (RAD; defined by Hurley et al., 2005). Due to 
the overlap between the different mortality endpoints, we included only cause specific mortality in the 
aggregate results. For PM
10
, lower respiratory symptoms (LRS) and new cases of chronic bronchitis were 
included.
For mortality, we used the relative risks as provided by Pope (Pope et al., 2002; WHO, 2006a,b). For 
morbidity, relative risks are based on the thorough review made for the CAFE estimates by Hurley et al. 
(2005) and WHO (2006b). The health endpoints and corresponding exposure-response functions are 
summarized in Table 3-19 in section 3.12. 
3.9.3 Exposure data
Annual population weighed mean ambient concentrations of PM
2.5
 and PM
10
 were estimated, similarly 
to the values for ozone, by the European Topic Centre on Air and Climate Change (ETC/ACC) using 
geographical modelling. Population density data were based on JRC data. For further details, see the ozone 
section. Exposure values are presented in Table 3-13 and summarized in Table 3-21 in section 3.12.
The calculations involve no reference concentration for estimating the PM effects, so all PM-related 
morbidity and mortality are included in the burden of disease estimates. This is in contrast to, for example, 
the CAFE calculations, in which only the impacts of European anthropogenic emissions were estimated. 
The EBoDE calculations include the contribution to PM from natural sources and sources outside Europe. 
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TABLE 3-13. National population weighted averages of ambient PM levels in 2005 for the target countries (de Leeuw 
and Horalek, 2009).
Country
 
Concentrations
PM10
(µg m-3)
PM2.5
(µg m-3)
Belgium 28.9 18.7
Finland 13.3 9.1
France 19.1 12.3
Germany 22.1 16.0
Italy 32.7 19.6
Netherlands 29.1 18.7
3.10 Radon
3.10.1 About radon
Radon is a short-lived radioactive gas that occurs naturally in soils and rocks. It is generated by the 
radioactive decay of uranium. Indoor radon concentrations differ based on the characteristics of the 
geological substrates beneath houses and the use of different building materials. 
Exposure to radon can lead to lung cancer. Studies to estimate the risk of lung cancer associated 
with residential radon exposure have been conducted in many European countries (Lagarde et al. 1997, 
Bochicchio, 2005, 2008; Darby et al., 2005, 2006). Radon is classified by IARC as carcinogenic to humans 
(type 1, 1988) with genotoxic action. No safe level of exposure can be determined (WHO, 2000a). Besides 
lung cancer radon is not known to cause other health effects. 
Radon has a synergistic effect with smoking. Epidemiological evidence suggests that the risk of 
simultaneous exposure to both tobacco smoke and radon is more than additive but that it may be less 
than multiplicative. 
3.10.2 Selected health endpoints and exposure-response functions
Radon effects are usually presented as additional cases of lung cancer at a certain exposure (i.e. unit risk 
model). In order to account for the interaction with smoking, however, a relative risk model seems more 
appropriate. We therefore calculated results using both a unit risk model and a relative risk model (method 
1A and 2A). The RR method (1A) is used in the final aggregate results. The radon UR model (UR=6.6E-07 
(Bq m-3)-1, Darby et al., 2005) is used for comparison of UR and RR modelling approaches in Chapter 5.
The relative risk model, as suggested by the meta-analysis of Darby et al. (2005), assumes the lung 
cancer risk from radon to be linearly proportional to the radon exposure, but also to the background 
lung cancer rate caused by tobacco smoking (and, to a lesser extent, by exposure to second-hand smoke, 
ambient air particulate matter and possibly some occupational exposures) (see Table 3-19 in section 3.12 
for the RR values). 
3.10.3 Exposure data
The soil uranium contents and respectively the residential radon concentrations vary significantly 
between the countries. Yet the differences within the countries are still far greater, and the indoor radon 
concentrations in individual buildings are essentially impossible to predict. Long-term average indoor 
radon concentrations, however, are relatively easy to measure and are therefore better known and 
comparable between the countries than those of any other indoor air contaminant.
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EBoDE uses the national residential radon exposure estimates as collected by the EU RadonMapping 
project (http://radonmapping.jrc.ec.europa.eu; country reports available from http://radonmapping.jrc.
ec.europa.eu/index.php?id=37&no_cache=1&dlpath=National_Summary_Reports, accessed 11 June 
2009). and the UNSCEAR 2000 Report, as presented in Table 3-14 and summarized in Table 3-21 in 
section 3.12. No further national data collection was conducted, but some additional international data 
sources were identified, notably from the WHO Radon project (IRP, 2010). 
TABLE 3-14. Radon concentrations in dwellings determined in indoor surveys (compiled from National Summary 
Reports at http://radonmapping.jrc.ec.europa.eu/ and UNSCEAR, 2000). The respective cancer risks are estimated 
from background lung cancer rates using both absolute and relative risk models.
Country AM 
(Bq m-3)
GM
(Bq m-3)
GSD % (of 
people 
exposed) › 
≥200 Bq m-3
% (of 
people 
exposed) › 
≥400 Bq m-3
Max
(Bq m-3)
Belgium 69 76 2.0 0.5 4 500
Finland 120 84 2.1 12.3 3.6 33 000
France 89 53 2.7 8.5 2.0 4 964
Germany 50 40 1.9 3.0 1.0 10 000
Italy 70 52 2.0 4.1 0.9 1 036
The Netherlands 30 25 1.6 0.3 0.0 382
AM: Arithmetic Mean; Bq: Becquerel; GM: Geometric Mean; GSD: Geometric Standard Deviation.
3.11 Burden of disease, health and population data
For this project, the harmonized health statistics database as held by the World Health Organization 
was used. This database provides health data specific for each country, health endpoint as defined by the 
Environmental Burden of Disease -programme, age group and gender. We used data (deaths and DALYs) 
for the year 2004 (WHO, 2009b; more detailed data available on request)(World Health Organization. The 
global burden of disease: 2004 update. Geneva: World Health Organization; 2009. Available at: http://www.
who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html). 
The data were obtained in discounted/age-weighted and undiscounted/un-age-weighted format. 
Depending on the type of calculation (see section 2.1), different data were needed. For calculations 
according to methods 1A and 2A (Table 3-19 shows which methods were used for which calculation), the 
total YLL and YLD were needed per age group and country. The WHO database provides data for pre-
defined age categories (e.g. 0–4; 5–14, etc). Age-specific values were derived assuming an equal distribution 
of people within the age categories in the WHO data. Table 3-15 shows a sample of the burden of disease 
as available from the WHO database, aggregated over all ages and for a selection of health endpoints only.
For calculations according to method 2B (see section 2.1 and Table 3-19), no background health 
data was applied; the incidences were calculated using a unit risk model and the burden of disease was 
estimated using the WHO disability weights and duration estimates. For these calculations (IQ loss and 
HTD from lead), no age-weighing was applied due to the lack of information on the age distribution 
of the effects; however, the impact of the simplification was estimated to be small and to affect only the 
discounted results. Table 3-16 shows the disability weights and durations that were used.
We have carried out preliminary calculations to investigate the potential effect of lag times on the 
discounted estimates. The lag times used per health endpoint are provided in Table 3-17. 
Population data (number of people in 2004) were used to calculate numbers of DALYs per million 
people and are provided in Table 3-18.
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TABLE 3-15. WHO burden of disease data (total undiscounted, not-age-weighted DALYs) in 2004 (sample of health 
endpoints; aggregated over all ages).
Health endpoint
YLL/ 
YLD
Burden of disease data (WHO) – discounted (3%) and age-weighted
Belgium Finland France Germany Italy Netherlands
Total mortality 
(non-violent)
Total morbidity
YLL 1 137 042 520 755 5 904 337 9 261 877 5 780 589 1 585 775
YLD
930 436 460 350 5 219 164 7 283 809 4 838 018 1 360 245
Total cancer
YLL 413 390 154 033 2 447 205 3 193 738 2 215 606 622 914
YLD 34 945 12 796 198 478 254 086 172 230 50 271
Leukaemia
YLL 15 490 5 586 99 669 119 106 93 212 22 131
YLD 487 167 3 222 3 845 2 859 689
Lung cancers
YLL 103 461 27 142 514 569 653 118 465 809 154 443
YLD 2 125 583 9 473 12 740 10 014 3 031
Otitis media
YLL n/a n/a n/a n/a n/a n/a
YLD 1 184 611 7 447 8 038 5 469 2 004
Ischemic heart 
disease
YLL 178 793 115 258 478 408 1 624 841 841 741 177 269
YLD 21 764 13 676 56 462 188 782 98 850 22 340
Cardiopulmonary 
disease
YLL 385 102 203 063 1 222 063 3 067 603 1 861 658 425 443
YLD 147 553 58 363 502 501 1 003 277 559 717 189 275
Chronic 
bronchitis
YLL 47 784 9 982 69 644 239 985 134 312 55 767
YLD 66 091 14 949 125 272 404 043 151 689 83 814
Asthma 
induction/ 
aggravation
YLL 4 632 935 17 794 31 851 9 902 1 882
YLD 13 818 9 264 99 867 100 872 60 658 31 209
Lower respiratory 
infections
YLL 30 003 13 331 97 589 168 799 78 505 44 596
YLD 629 361 1 981 3 721 2 317 1 072
Sum of all above
YLL 2 313 816 2 313 816 2 313 816 2 313 816 2 313 816 2 313 816
YLD 1 220 913 1 220 913 1 220 913 1 220 913 1 220 913 1 220 913
DALY 3 534 729 3 534 729 3 534 729 3 534 729 3 534 729 3 534 729
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TABLE 3-16. Input parameters for calculating the burden of disease (method 2B).
Stressor Health endpoint
Disability 
Weight
Duration (yrs)
Lead Mild mental retardation 0.36 77.6
Hypertensive disease 0.2 3.6
Road traffic noise High sleep disturbance (HSD) 0.07 a) 1
Railway noise High sleep disturbance (HSD) 0.07 a) 1
Aircraft noise High sleep disturbance (HSD) 0.07 a) 1
Ozone Minor restricted activity days 0.07 b) 0.00274 (= 1 day)
Cough days, children 0.07 b) 0.00274 (= 1 day)
LRS days in children (excl cough) 0.099 c) 0.00274 (= 1 day)
PM2.5 Restricted activity days (RAD) 0.099 
c) 0.00274 (= 1 day)
a) Disability weight proposed by the WHO working group for noise impact assessment (confidence intervals 0.04–0.09).
b) Disability weight for pharyngitis.
c) Disability weight for lower respiratory infections (chronic sequelae).
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TABLE 3-17: Crude estimated lag times (time between exposure to the onset of the disease) as used in the lag-time 
model (author estimates in years).
Environmental 
stressor
Health endpoint Crude estimated lag time 
(author judgement) 
years
Benzene Leukaemia 3
Dioxins Total cancer incidence 10
SHS Tracheas, bronchus and lung cancers in 
non smokers
30
Ischemic heart disease 3
Asthma induction, adults (>21 yr) 1
Asthma induction, children (<14 yr) 1
Lower respiratory infections (<2 yr) 0
Otitis media (<3yr) 0
Formaldehyde Asthma aggravation (children) 0
Lead IQ loss 3
Hypertensive disease 1
Transport noise High sleep disturbance (HSD) 0
Ischemic heart disease (IHD) 3
Ozone Total mortality (non-violent) 1
Minor restricted activity days 0
Cough days, children 0
LRS days in children 0
PM2.5 Cardiopulmonary mortality * 3
Lung cancer mortality * 30
Total mortality (non-violent) * 3
Chronic bronchitis 1
Restricted activity days (RAD) 0
PM10 LRS symptoms days, children 0
LRS symptom days, adults 0
Radon Lung cancer 30
* Overlapping end-points.
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TABLE 3-18. Population sizes (in 2004; millions) in the defined target population groups (WHO, 2009b: Reference populations and live births).
Populations (in millions) Belgium Finland France Germany Italy Netherlands Total
All 10.2 5.2 60.6 82.5 58.2 16.3 233.1
Infants (<2 yr) 0.229 0.113 1.530 1.452 1.090 0.399 4.8
Toddlers (<3 yr) 0.345 0.169 2.296 2.197 1.629 0.603 7.2
Children (0-4 yr) 0.58 0.28 3.83 3.69 2.71 1.02 12.1
School children (5–14 yr) 1.23 0.63 7.39 8.35 5.51 2.00 25.1
Children (<14 yr) 1.7 0.851 10.5 11.2 7.7 2.8 34.6
Adults (>15 yr) 8.4 4.3 49.4 70.5 50.0 13.3 195.8
Adults (>15 yr) with chronic LRS * 2.5 1.3 14.8 21.1 15.0 4.0 58.8
Non-smoking adults (>15 yr) 6.3 3.2 35.3 50.0 38.2 8.8 141.9
Adults (>21 yr) 7.7 3.9 44.7 64.7 46.4 12.1 179.6
Adults (>27 yr) 6.9 3.5 40.0 58.9 42.2 10.9 162.5
Adults (>30 yr) 6.5 3.3 37.8 56.1 39.8 10.3 153.8
Adults (15-64 yr) 6.7 3.5 39.5 55.4 38.7 11.0 154.7
Working age (18–64 yr) 6.3 3.3 37.1 52.5 37.0 10.4 146.7
* Adults with chronic respiratory symptoms estimated in CAFE to be 30% (Watkiss et al, 2005).
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3.12 Data overview (tables)
TABLE 3-19. Summary of health endpoints, exposure units and exposure/response-relationships. Unless otherwise stated, both mortality and morbidity were estimated.
Stressor Health endpoint Population Exposure estimate
Unit of 
exposure
Type 
of ERF
Point estimate 
of ERF a)
LCL (95%) UCL (95%) Reference(s) for ERF Threshold
Calcu-
lation 
method b)
Benzene Leukemia All Annual mean 
exposure
µg m-3 UR 6.00 x 10-6 2.20 x 10-6 7.80 x 10-6 WHO, 2000a; IRIS 2003 2A
Dioxin Total cancer incidence All Daily intake of 
adults
pg/kg/d UR 1.00 x 10-3 5.70 x 10-4 5.10 x 10-3 NAS, 2004, IRIS, 2006, 
Leino 2008
2A
SHS Tracheas, bronchus and lung 
cancers c)
Adult non-
smokers
% of people 
exposed (= yes)
yes/no RR 1.21 1.13 1.30 US S.G., 2006 1A
Ischemic heart disease Adult non-
smokers
yes/no RR 1.27 1.19 1.36 US S.G., 2006 1A
Asthma induction Adult non-
smokers
yes/no RR 1.97 1.19 3.25 Jaakkola et al., 2003 1A
Asthma induction Children (<14 yr) parental 
y/n
RR 1.32 1.24 1.41 Cal-EPA, 2005 1A
Lower respiratory infections Infants (<2 yr) parental 
y/n
RR 1.55 1.42 1.69 US S.G., 2006 1A
Otitis media Toddlers (<3 yr) parental 
y/n
RR 1.38 1.21 1.56 Etzel et al., 1992; Cal-
EPA 2005
1A
Formal-
dehyde
Asthma aggravation (children)
(morbidity only)
Toddlers (<3 yr) Annual mean 
residential indoor 
concentration
µg m-3 RR 1.017 1.004 1.025 Rumchev et al., 2002 100 1A
Lead IQ loss Children (<5 yr) Distribution of 
blood lead levels
µg/l UR 0.051 0.032 0.07 Landphear et al., 2005 24 2B
Mild mental retardation
(morbidity only)
Children (<5 yr) µg/l DS d) function - - - 24 2B
Hypertensive diseases
(morbidity only)
Adults/All µg/l DS d) function - - - 50 2B
Increased blood pressure Adults/All µg/l UR 2.50 x 10-2 1.70 x 10-2 3.20 x 10-2 Fewtrell et al. 2003, 
Schwartz, 1995
50 2B
Road traffic 
noise
High sleep disturbance (HSD)
(morbidity only)
All Persons exposed 
to predefined 
exposure 
categories
Lnight (dB) UR function function function Miedema et al., 2007 2B
Ischemic heart disease (IHD) All Lday16h 
(dB)
OR function function function Babisch, 2006 1A
Railway 
noise
High sleep disturbance (HSD)
(morbidity only)
All Lnight (dB) UR function function function Miedema et al., 2007 2B
Aircraft 
noise
High sleep disturbance (HSD)
(morbidity only)
All Lnight (dB) UR function function function Miedema et al., 2007 2B
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Stressor Health endpoint Population Exposure estimate
Unit of 
exposure
Type 
of ERF
Point estimate 
of ERF a)
LCL (95%) UCL (95%) Reference(s) for ERF Threshold
Calcu-
lation 
method b)
Ozone Total mortality (non-violent) Adults (>30 yr) Population 
weighed ambient 
SOMO35 level
µg m-3 RR 1.0003 1.0001 1.000 WHO, 2006a 1A
Minor restricted activity days
(morbidity only)
Working age 
(18–64 yr)
µg m-3 UR 0.0115 0.0044 0.02 Hurley et al., 2005, WHO 
2006b
2B
Cough days, children
(morbidity only)
School children 
(5–14)
µg m-3 UR 0.093 0.019 0.22 Hurley et al., 2005, WHO 
2006b
2B
LRS days in children (excl cough)
(morbidity only)
School children 
(5–14)
µg m-3 UR 0.016 -0.043 0.08 Hurley et al., 2005, WHO 
2006b
2B
PM2.5 Cardiopulmonary disease Adults (>30 yr) Population 
weighted ambient 
level
µg m-3 RR 1.0077 1.0020 1.0132 Pope et al., 2002, WHO, 
2006a
1A
Lung cancer Adults (>30 yr) µg m-3 RR 1.012 1.004 1.020 Pope et al., 2002, WHO, 
2006a
1A
Chronic bronchitis 
(new cases)
Adults (>27 yr) µg m-3 UR 5.33 x 10-5 1.70 x 10-6 1.13 x 10-4 Hurley et al., 2005, 
WHO, 2006b
1A
Restricted activity days (RAD) 15–64 yr µg m-3 UR 0.0902 0.0792 0.101 Hurley et al., 2005, 
WHO, 2006b
2B
Radon Lung cancer All Residential mean 
level
Bq m-3 RR 1.0016 1.0005 1.0031 Darby et al. 2005 1A
a) These exposure response functions are all expressed per 1 unit of exposure.
b) Different types of calculation methods were applied (see also paragraph 2.1):
   1A: Deriving the PAF from epidemiological data; applying the PAF to total burden of disease data (WHO database)
   2A: Indirectly calculating the PAF from the Unit Risk and background incidence; applying the PAF to total burden of disease data (WHO 
   database)
   2B: Using a Unit Risk to calculate Attributable Incidence; calculating the Burden of Disease: AI x DW x L
c) The RR for spousal smoking is used as a proxy for any regular exposure (including at work).
d) For lead, a shift in exposure distributions is linked to a unit risk approach. Further information provided in 3.6. 
Function: No point estimate can be given, as the exposure response function is given by a more complex function. 
AI = Attributable Incidence; 
ARI = Acute respiratory infections; 
Bq = Becquerel; 
IHD = Ischemic heart disease; 
Lday16h = noise level for day and evening; 
LRS = Lower respiratory Symptoms; 
PCB = Polychlorinated biphenyls, 
PAF = Population Attributable Fraction; 
PM = Particulate Matter; 
RAD = Restricted activity days; 
SHS = Second-Hand Smoke, 
SOMO35 = sum of maximum 8-hour ozone levels over 35 ppb (70 µg/m3); 
UR = Unit Risk; 
RR = Relative Risk; 
yr = year; µg = microgram; mg = milligram; pg = picogram; kg = kilogram; d = day
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TABLE 3-20. Summary of years and sources of exposure data.
Stressor Year(s) of 
original 
exposure 
data
Assumptions for 
trends estimation to 
2004
Exposure data source
Benzene 2004 National trend 
estimates when 
applicable
AirBase data for outdoor levels in 2004; 
national studies for indoors
Dioxins 1997–2006 No trend assumed National data for intake
Second-hand smoke 2008 Available data fitted 
with power functions 
for trends
National and international survey data for 
exposures between 1990 and 2008 used for 
modelling 2004 data; 
Formaldehyde 1990–2005 No trend assumed National indoor concentration data
Lead 1990–2005 National trend 
estimates
National blood lead level data
Transport noise 2007¹ No trend assumed EC Environmental Noise Directive data
Ozone 2005 No trend assumed ECT/ACC spatial model based on AirBase 
observations and air quality maps 
Particulate matter 2005 No trend assumed
Radon up-to 2005 No trend assumed RadonMapping project (http://radonmapping.
jrc.ec.europa.eu) and the UNSCEAR 2000 Report
¹ Target year of END data was set as 2007. The actual collected data contains subsets of data from various years.
3   Selected exposures and health effects
55
Report 1/2011
N
ational Institute for H
ealth and W
elfare (TH
L)
European Perspectives on
Environm
ental Burden of D
isease
TABLE 3-21. Summary of exposure values for benzene, dioxin and dioxin-likes, SHS, formaldehyde, lead and radon for 2004, ozone and PM for 2005.*
Environmental stressor Population group Exposure metric Unit Belgium Finland France Germany Italy Netherlands
Benzene All Average annual exposure 
concentration
µg m-3 1.5 2.0 2.1 1.8 2.9 0.9
Dioxins and dioxin-like 
PCBs
All Average annual daily intake pg TEQ/kg/d 1.9 1.5 2.3 2.0 2.3 1.0
SHS All Percentage of non-smokers % 74.9 74.2 71.5 71.0 76.5 66.6 
Non-smokers Percentage of non-smokers exposed % 32 14 25 31 30 30 
Children Percentage of non-smokers exposed % NA 4 33 24 40 36 
Formaldehyde (threshold 
100 µg m-3)
All Percentage of people exposed above 
100 µg m-3
% 0.20 2.30 0.20 0.30 0.05 0.05 
All Average indoor concentration above 
100 µg m-3
µg m-3 139 122 118 113 101 101
Lead All Average blood concentration? µg/l 22 16 25 22 39 19
Adults Percentage of adults exposed above 
50 µg/l
% 5.5 1.8 8.1 5.5 23.9 3.4 
Adults Average blood concentration for 
adults above 50 µg/l
µg/l 68 68 68 67 76 65
Children 0–4 Percentage of children exposed above 
24 µg/l
% 32.5 17.0 39.9 32.5 67.1 24.7 
Children 0–4 Average blood concentration for 
children above 24 µg/l
µg/l 39 36 41 39 50 37
Ozone All Annual sum of ozone maximum 8-h 
levels above 35 ppb (SOMO35)
µg m-3 2 787 2 580 4 756 4 164 8 134 1 920
PM2.5 All Average annual ambient 
concentration
µg m-3 18.7 9.1 12.3 16.0 19.6 18.7
PM10 All Average annual ambient 
concentration
µg m-3 28.9 13.3 19.1 22.1 32.7 29.1
Radon All Average annual indoor concentration Bq m-3 69 120 89 50 70 30
‘ Noise data are not included in this overview table, as they cannot be easily summarized due to categorial exposures. For noise data, please see paragraph 3.7.
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4 Environmental burden of disease    
 estimates
In the EBoDE project, we have calculated the environmental burden of disease for nine stressors in six 
countries, for the year 2004. The following paragraphs present and discuss the results of these calculations. 
The primary results are presented as undiscounted, un-age-weighted DALYs per million people. In 
addition to the results presented in this chapter, Appendix A presents the results per country.
Calculations were based on the most recent scientific evidence concerning population exposure-
response functions, national exposure data, and WHO burden of disease data and methods for estimating 
disease burden where available. Even though the most recent scientific knowledge and data were used, 
many uncertainties and controversies remain (see Chapter 5). Results give only a crude ranking of 
environmental burden of disease associated with the stressors and need to be interpreted with caution. 
4.1 Overall results 
The results of the EBoDE project suggest that 3–7% of the standard WHO discounted age-weighted burden 
of disease in the participating countries is associated with exposure to the selected nine environmental 
stressors. The aggregate results for all stressors are shown in Figure 4-1, which also indicates the relative 
scientific strength of the evidence underlying the estimates. The quantitative uncertainty ranges provided 
in this figure are based on qualitative and semi quantitative evaluations of the uncertainties and author 
judgment.
FIGURE 4-1. Relative public health impact of the selected environmental stressors in undiscounted un-ageweighted 
DALYs per population of a million in the participating countries. Numerical ranges reflect quantitative uncertainty 
in the average estimate. Variability between countries is in many cases much larger. (* =numerical model used in 
estimating threshold exceedances).
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Numerical values indicate non-discounted DALYs per million people in the six participating countries.
* a numerical model has been used to estimate threshold exceedances.
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Figure 4-2 shows the burden of disease related to the nine stressors proportional to each other. As can be 
seen from this figure, particulate matter (using PM
2.5
 as indicator) is estimated to be the leading factor 
associated with 6.000 to 10.000 non-discounted DALYs per million people. Overall, PM
2.5
 is responsible 
for approximately two thirds of the environmental burden of disease related to the nine stressor evaluated 
in EBoDE. After PM, transportation noise, second hand smoke and radon contribute to the largest share of 
the environmental burden of disease. These four factors together are estimated to be responsible for over 
90 % of the total studied environmental burden of disease.
FIGURE 4-2. Relative contribution of the nine targeted stressors to the burden of disease (undiscounted, un-age-
weighted DALYs) attributed to these stressors, average over the six participating countries.
The quantitative results of the environmental burden of disease calculations per stressor and health 
endpoint, averaged over the six countries, are presented in Table 4-1. The total results aggregated per 
stressor are shown in Table 4-2.
When we look at effects on mortality, the studied nine factors are estimated to be associated with 
approximately 1.6 million years of life lost (YLL, non-discounted, not age-weighted) in the participating 
countries in the 2004, or 6 900 YLL per a million inhabitants (Table 4-3). For most of the stressors, the 
impacts are dominated either by morbidity (formaldehyde, lead and traffic noise) or by mortality (benzene, 
dioxins, and radon). We realize that the selection of health endpoints and further assumptions are partly 
responsible for this effect. For dioxin, for example, all DALYs are due to mortality (i.e. YLL), as all cancers 
are assumed to be fatal in our estimates. 
PM
Radon
Dioxins
Ozone
Noise
SHS
Formaldehyde
Lead Benzene
Non-discounted values
2.5
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TABLE 4-1. Burden of disease in DALYs per million people for each stressor and endpoint, averaged over the 
participating countries.
 
Stressor
 
 
Endpoint
 
Non-discounted Discounted with lag Difference
%Total
DALY
DALY per 
million
Total
DALY
DALY per 
million
Benzene Leukemia 741 3 341 1 -54 %
Dioxin Total cancer incidence 112 332 482 42 429 182 -62 %
SHS Lung cancers in non 
smokers
19 381 83 3 989 17 -79 %
Ischaemic heart disease 157 919 678 68 154 292 -57 %
Asthma induction, adults 
(>21 yr)
30 363 130 23 892 103 -21 %
Asthma induction, children 
(<14 yr)
10 481 45 9 988 43 -5 %
Lower respiratory 
infections (<2 yr)
1 414 6 595 3 -58 %
Otitis media (<3 yr) 654 3 270 1 -59 %
Formaldehyde Asthma aggrevation 
(<3 yr)
20 0 16 0 -23 %
Lead IQ loss 106 621 457 31 453 135 -70 %
Increased blood pressure 2 930 13 2 736 12 -7 %
Road traffic 
noise
High sleep disturbance 
(HSD)
167 916 720 167 916 720
Ischaemic heart disease 
(IHD)
13 105 56 5 890 25 -55 %
Railway noise High sleep disturbance 
(HSD)
12 253 53 12 253 53
Aircraft noise High sleep disturbance 
(HSD)
7 202 31 7 202 31
Ozone Total mortality (non-
violent)
8 365 36 8 122 35 -3 %
Minor restricted activity 
days
4 484 19 4 484 19
Cough days, children 6 042 26 6 042 26
LRS days in children 1 470 6 1 470 6
PM2.5 Cardiopulmonary mortality 1 081 750 4 642 499 063 2 141 -54 %
Lung cancer mortality 348 623 1 496 72 512 311 -79 %
Chronic bronchitis (COPD) 289 711 1 243 151 089 648 -48 %
Restricted activity days 
(RAD)
61 003 262 61 003 262
Radon Lung cancers 194 277 834 40 563 174 -79 %
* In calculations according to method 2B (see Table 3-19 and section 2.1), discounting, when applicable, was used without age-weighing. 
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TABLE 4-2. Aggregate burden of disease by stressors per country for 2004/2005, in undiscounted, un-age-weighted 
DALYs per million people.
Stressor Belgium Finland France Germany Italy Netherlands Average
Benzene 2.5 3.0 3.4 2.7 4.2 1.6 3.2
Dioxin 453 330 586 466 483 242 482
SHS 1 110 891 550 1 235 975 749 945
Formaldehyde 0.2 1.6 0.1 0.1 0.0 0.0 0.1
Lead 298 118 461 235 946 217 470
Traffic noise 437 371 1 483 591 734 775 860
Ozone 52 47 81 73 138 34 87
PM2.5 10 462 4 602 4 572 8 384 9 378 8 322 7 642
Radon 1 078 926 1 146 620 866 453 834
Total 13 892 7 289 8 883 11 608 13 525 10 793 11 324
TABLE 4-3. Mortality and morbidity components of the non-discounted burden of disease by stressor in the six 
participating countries per population of a million. Cases where over 90 % of the burden of disease is caused by 
either morbidity or mortality are highlighted in color blue and bold. 
Stressor
 
Deathsa YLD YLL DALY YLL
per year per year per year per year %
Benzene 0.2 0.1 3.1 3.2 97 %
Dioxin 30 36 446 482 93 %
SHSb 78 n/a n/a 945 n/a
Formaldehyde 0.0 0.1 0.0 0.1 0.6 %
Lead 0.0 470 0.1 470 0.02 %
Traffic noise 4.2 810 50.3 860 5.8 %
Ozone 36 51 36 87 41 %
PM2.5 516 2 063 5 580 7 642 73 %
Radon 51 16 817 834 98 %
Total 715 3 446 6 933 11 324 61 %
a Numbers of deaths are not valid indicators for some effects (see Chapter 5).
b YLL+YLD split not available for SHS due to the different method of calculation.
4.2 Results by stressor
Figure 4-3 at the end of this paragraph shows the results (not discounted, not age-weighted) per stressor 
and per country. 
4.2.1 Benzene
Based on the available information about leukaemia, the total impact of benzene on public health is 
estimated to be low (see Figure 4-1 and Figure 4-2). Benzene impacts are the highest in Italy and the 
lowest in the Netherlands. The great quantity of two-wheelers with two-stoke engines in Italy may partly 
explain the high benzene exposures. The low benzene related burden of disease in the Netherlands is due 
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to the lowest exposures. In France, data reflect a large number of dwellings, while in other countries data 
are limited to a smaller number of monitored houses; thus the high burden estimate for France is based 
on more reliable data than the other estimates. In addition, the presence or absence of tobacco smoke 
in indoor environments is not always reported, making comparison more difficult. This at least partly 
explains the higher levels in Finland, where benzene from smoking was included and was estimated to 
contribute approximately one third of the exposures (see also Table 3-1 in section 3.2). 
Further sources of uncertainty in the benzene related burden of disease estimates relate mainly to the 
availability of exposure data, exclusion of other health effects than leukaemia, and the potential interaction 
of benzene with other components of tobacco smoke.
4.2.2 Dioxins and dioxin-like PCBs
The relative burden of disease related to dioxins is estimated to be medium (see Figure 4-1 and Figure 4-2), 
however, uncertainties are large. Effects of dioxins cannot easily be distinguished from other occupational 
risk factors; low-dose effects are very difficult to assess; thresholds for effects are mostly unknown; and 
exposure data are often only indirectly available. Our estimates only include effects of dioxins on total 
cancer incidence. This is a rather crude aggregate end-point. In addition, each cancer case was assumed 
to be fatal during the first year, which may also have lead to overestimation. Also, numerous more specific 
health end-points (see paragraph 3.3) were not modelled. Therefore, it is yet unclear whether our estimates 
over- or underestimate the total burden of disease.
The burden of disease related to dioxin exposure is relatively low in Finland and the Netherlands, 
and highest in France. Potential explanations for this are different eating habits and differences in food 
contamination. But also the different methods to evaluate the daily intake may contribute to an unknown 
extent of uncertainty.
4.2.3 Second hand smoke
The burden of disease related to SHS is estimated to account for 600-1200 DALYs per million people 
(medium impact). As outlined in paragraph 3.4, not all health effects could be included in the calculations 
due to unavailability of statistics. Besides, uncertainties in our estimates relate to e.g. survey-based exposure 
measurements (as opposed to measuring personal exposures), relative risks and the various assumptions 
made in the method (e.g. smokers are not susceptible to SHS). The provided range around the best estimate 
has been based on a sensitivity analysis varying the main assumptions made in the method. Nonetheless, 
most evidence for SHS-related impacts is fairly consistent, and the estimates of the burden of disease are 
considered relatively stable.
Burden of disease from second hand smoke are remarkably low in France and high in Germany. 
Potential explanations for the higher levels in Germany are the slightly higher exposure levels combined 
with higher prevalence of the relevant diseases, such as ischaemic heart disease, which increases the 
susceptibility to the risk factor.
The disease burden due to SHS is still substantial. Trends, however, are decreasing due to European-
wide implementation of smoke-free policies to reduce SHS exposure. The predicted exposure reductions 
between 2004 and 2010 as presented in Tables 3.7 and Table 4-5 are quite significant. 100% smoke-
free policies have shown significant reductions in mortality and should be implemented in all indoor 
workplaces, public places and public transports. Complementary educational strategies may be necessary 
to extend the protection of children and adult non-smokers at home.
4.2.4 Formaldehyde
The burden of disease related to formaldehyde, based on asthma incidence in children under 3 years of age, 
is estimated to be relatively low. However, the consistency of the knowledge base is low, with uncertainties 
related to the difficulty of establishing a threshold for effects, a lack of epidemiological data and a large 
discrepancy in widely used models.
Formaldehyde exposures are remarkably high in Finland (see also Figure 3-3). The absolute average 
concentration levels do not vary so drastically between the countries. However, because a threshold of 
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100 µg m-3 was applied, the relative differences between countries increased. The formaldehyde levels in 
Finland are higher than in many other developed countries due to the types of construction materials used 
and the relatively tightly sealed buildings. 
The risk estimates for formaldehyde depend strongly on the chosen threshold level. Even though 
identified as a known human carcinogen, it is likely that cancer effects are negligible in Europe, due to 
the fact that almost all exposures are below the threshold level as proposed by WHO (2000a, 2011). The 
currently available exposure data cannot be used for reliably estimating the fraction of the population 
that is exposed to formaldehyde level exceeding the threshold levels. That is caused by the fact that 
current formaldehyde monitoring techniques are not suitable for detecting peaks of exposure, which may 
occur during some domestic tasks or soon after home refurbishment, especially in the absence of proper 
ventilation. Other common sources of formaldehyde, such as widespread use of fragrances and SHS, may 
also cause exceedance of the threshold value. This may cause underestimation of the true formaldehyde-
related burden of disease. 
4.2.5 Lead
Lead is estimated to contribute to 100-500 DALYs per million people (medium impact, see Figure 4-1 
and Figure 4-2). These estimates are based on a limited population representativity and partly older data 
with uncertain trend estimations (see paragraph 3.6). Other uncertainties relate to the availability of dose-
response functions over the complete exposure spectrum, and the aggregation of effects. Lead impacts have 
only been based on IQ loss and mild mental retardation. At least at higher exposure levels that prevailed 
during earlier decades, lead exposures were associated with a larger number of health endpoints, ranging 
from hearing impairment to kidney failures. However, the evidence for these effects at the prevailing 
low level exposures is very limited (WHO, 2007b). Nonetheless, our burden of disease estimates may 
underestimate the true lead-related burden of disease (see also Chapter 5). 
Lead exposures are the highest in Italy. One of the most important reasons for this may be the relatively 
old age group in which blood lead levels were measured. As was shown in paragraph 3.6, the blood lead 
levels in Italy were presented for people aged 18–64 years. In the Netherlands, in contrast, the sample 
included children aged 1–6 years. Because lead accumulates in the body over the years, this is probably the 
most important reason for lead-related burden of disease in the Netherlands being relatively low and in 
Italy relatively high. In addition, the data for Italy (Apostoli et al., 2002) are quite old (from 2000). Lead 
levels are expected to be lower in 2004. 
Some other uncertainties that may affect the comparability of lead results among countries include 
the fact that data from Finland, Germany and the Netherlands are not representative for the age-group 
considered (let alone for the whole population); and that some countries provided a Geometrical Mean 
(GM) instead of an Arithmetical Mean (AM). The GM is expected to be lower than AM, because there are 
few high values within the samples.
4.2.6 Transportation noise
Since so many people are exposed to noise, the total associated disease burden is substantial despite 
the relatively small disability weights (0.04-0.09) and is estimated to cause an undiscounted, un-age-
weighted average of 860 DALYs per million people. Transportation noise plays a great role in each included 
country but there are numerous differences between the countries. DALYs range from about 371 per 
million inhabitants in Finland (less densely populated and highly urbanized but with only very few cities 
with more than 250 000 inhabitants) up to 1 483 DALYs per million people in France (due to the fact that 
only data for the greater Paris area were available). These differences point out some major limitation due 
to incomplete exposure data from environmental noise directive reporting (for Belgium e.g. only available 
for the Flanders region) and due to different population and traffic densities in the countries. 
Furthermore, a strong limitation results from the fact that exposure data reported in the first stage 
of END-reporting represent only “hot spots” where noise levels are supposed to be much higher than in 
the countryside. Therefore, the results from the calculations are an underestimation of the total burden 
of a country but may be overestimating the risks when applied for the whole population of a country 
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(as done when normalized by million inhabitants). Country comparability consequently is affected by 
the variability of representativity (more representative in highly urbanized countries). In addition, only 
exposure levels above L
night
 50dB (L
den
 55 dB) were available from the END database, so no health impacts 
could be calculated for the lower exposure levels.
Of all the estimated DALYs for transport noise, 94 % result high sleep disturbance (HSD). Because 
so many people are estimated to suffer from HSD, the DALYs are very sensitive to changes in the disability 
weight (with confidence intervals ranging from 0.04 to 0.09) and less sensitive to changes in exposure 
levels (e.g. due to other constant used for conversion of L
den
 to L
night
) or the exposure-response-functions. 
Further uncertainties result e.g. from missing exposure-response-functions for certain transport sources.
Other potential sources of uncertainty relate to individual and societal factors affecting noise levels 
indoors (such as regular location of sleeping rooms, window opening habits, window insulation etc.), and 
exogenous factors affecting those habits (such as climatic prerequisites and house ownership). 
4.2.7 Ozone
The relative impact of ozone on public health is medium (40-200 undiscounted, age-weighted DALYs), 
see Figure 4-1 and Figure 4-2. Even though not all health effects could be included, the selected morbidity 
health endpoints are estimated to account for 90% of the total effects. Uncertainties in the calculations 
relate, amongst other issues, to the estimated number of years of life lost for mortality. 
Ozone impacts are highest in the Mediterranean countries, represented here by Italy, as can be 
expected. Levels in the Netherlands are the lowest, probably because meteorological factors and relatively 
high levels of nitrogen oxide pollution consuming atmospheric ozone in congested areas.
Ozone levels have been slowly increasing during the last decade and due to the secondary nature of 
ozone air pollution, reduction of the exposures is challenging. From the point of view of health impact 
assessment the duration of loss of life at death is a key factor that hopefully will be estimated more 
accurately in future.
4.2.8 Particulate matter (PM)
In the six participating countries PM is estimated to cause a loss of 1.8 million DALYs annually, including 
1.3 million years of life lost due to mortality (73% of the total DALYs). Overall 67 % of the estimated 
environmental burden of disease in the EBoDE study was explained by exposure to PM
2.5
 making it the 
most significant environmental factor affecting public health (see Figure 4-1 and Figure 4-2). 
Uncertainties in the PM related burden of disease relate to the exposure-response functions for e.g. 
chronic bronchitis; and the potential of double counting of morbidity effects by combining the restricted 
activity days and lower respiratory symptom days. Overall, the PM epidemiology has been most thoroughly 
reviewed of the stressors included in this study. In the context of the CAFE study the estimates calculated 
for total and cause specific mortality were debated; the scientific evidence and mechanistic understanding 
of the causal processes are stronger for cardiopulmonary causes, but the effect estimates are higher for 
total non-violent mortality. We followed the CAFE approach to report the slightly lower cause specific 
results, which also can be used to meaningfully look at the ratio of mortality versus morbidity impacts.
Particulate matter impacts are the lowest in Finland and France and the highest in Belgium and Italy, 
which are known to be hotspots of particulate matter air pollution.
Annual average concentrations of PM
10
, monitored in EU urban background locations, show no 
significant decrease over the period 2000–2007 (Airbase, 2009). Available data are still too limited for 
reliable assessment of PM
2.5
 trends, but particulate matter exposures are expected to have a very slight 
downward trend due to the improvements in vehicle engine technology and emission controls in industry 
and energy production. However, the emissions of resuspended particles created by road traffic are 
expected to continue to grow due to the increasing traffic volumes.
A significant reduction in current PM levels could be achieved only if all feasible emission reduction 
measures were implemented (the maximum feasible reduction scenario) (WHO, 2010c). This is a challenge 
for the current policy as it involves the implementation of new technologies (e.g. low-emission diesel cars) 
and the creation of conditions that support individual behavioural change. The use of health impact 
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assessments as a standard tool in air quality and health policy, together with follow-up programmes 
(accountability) focusing on health consequences, is urgently needed across the Region (WHO, 2010c).
4.2.9 Radon
Radon is estimated to contribute 600-900 DALYs (undiscounted) per million people in the participating 
countries (see Figure 4-1 and Figure 4-2).
The radon related burden of disease is the highest in France and Belgium; and lowest in the Netherlands. 
These differences are mainly caused by the differences in geological substrates beneath houses and the use 
of different building materials. For example, in Belgium the average radon concentration in houses is 35 
Bq/m3 for Flanders and 70 Bq/m3 for Wallonia (southern part of the country). This difference is mainly 
due to the larger uranium concentration in rocks present in the southern part. On top, there are often 
relatively more cracks in these rocks simplifying the release of radon. Concentrations of radon in houses 
of more than 400 Bq/m3 are sometimes measured in the southern part of Belgium. Measures as placing 
an impermeable screen and adapting the ventilation system may substantially reduce the radon indoor 
concentration. 
For radon, we have used a relative risk to calculate cases of lung cancer (see paragraph 3.10). However, 
for this specific stressor, it is also possible to calculate attributable cases using a unit risk. The UR model is 
presented as part of the uncertainty analyses in Chapter 5.
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FIGURE 4-3. Undiscounted, un-age-weighted DALYs per million people per country.
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4.3 Results by country
Using the WHO global burden of disease database (see section 3.11), we have estimated for each country 
what the fraction of the total burden of disease is that can be attributed to the nine environmental stressors 
considered in EBoDE. The results are shown in Figure 4-4.
This environmental fraction ranges from 3% in Finland to 6.5% in Italy. Relatively, Finland has the 
largest BoD and the smallest EBD, while for Italy this is vice versa.
FIGURE 4-4. Environmental fraction attributable to the studied nine stressors (in blue) of the total burden of disease 
in the participating countries (discounted age-weighted DALYs per million people).
The results for individual countries are presented in appendix A. These can be used to look at the 
environmental burden of disease from a country perspective, and to see which factors contribute 
substantially in specific countries, relative to their contribution in other countries.
When comparing the relative contribution of all stressors per country, radon has the highest relative 
contribution in Finland. Relatively, the disease burden in France has the lowest contribution from PM. 
SHS comes only on the fifth place in France, whereas in other countries SHS is usually in the top of the 
contributors. On the other hand, traffic noise relatively has the largest contribution in France, due to the 
fact that only data from agglomerations are included in our estimates for France.
Relatively, the disease burden in Italy has the highest contribution of ozone. Italy is also the only 
participating country where the impact of lead exceeds that of ozone. Formaldehyde did not exceed the 
threshold in Italy, resulting in zero estimates. Also in the Netherlands, formaldehyde exposures did not 
exceed the threshold, resulting in zero estimates.
In Belgium, the impact of air pollution by particulate matter is relatively largest. Flanders is the Western 
European hot spot for PM pollution (IIASA, 2004). This situation is caused by a high population density, 
an intense industrial activity and a large volume of transit traffic linked to important harbors. The daily 
PM10 standard, enforced by the European Commission (1999/30/EC) is still being exceeded more times 
than allowed in Flanders.
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4.4 Trends and policy implications
The main results of EBoDE are calculated for the year 2004 (2005 for PM and ozone). This was one of 
the latest years for which exposure and health data were still relatively completely available. The original 
objective of the project was set as estimation of the environmental burden of disease also for the present 
situation, year 2010. However, due to difficulties in collecting national data, reliable trend analysis for all 
the stressors in all the participating countries proved to be too challenging for the given time and resources. 
For many of the stressors sufficient data for reliable trend analysis was not available (e.g. formaldehyde, 
lead) or the variability was too large for identifying trends with statistical significance (e.g. ozone, dioxins).
However, in order to gain insight into the use of the EBD assessment methodology and the potential 
use of burden of disease estimates in developing and evaluating environmental policies, we also estimated 
exposure trends for the year 2010 (Table 4-4). Country specific factors affecting the trends were not 
evaluated due to the lack of data and statistical difficulties in the trend estimation. Only for second-hand 
smoke exposures, national trends were derived separately (see Table 4-5 and Figure 3-2). 
TABLE 4-4. Crude estimated exposure trends from 2004 to 2010.
Stressor Estimated trend 
from 2004-2010
Remarks
Benzene -2% per year Model based on trends in outdoor data. Decreasing indoor smoking 
may also lead to lowering exposures from SHS
Dioxin No trend Large variability and limited data availability hinder identification of 
a reliable trend
Second-hand 
smoke
-4% per year
(see country data 
below)
Power model based on numerous data points from national and 
international surveys conducted between 1990 and 2008. 
Formaldehyde No trend Large variability and limited data availability hinder identification of 
a reliable trend
Lead No trend Trend could also be slightly lowering.
Noise No trend Trend could also be slightly increasing.
Ozone No trend Increasing trends may occur in rural areas. Large year-to-year 
variation
PM2.5 -2% per year AirBase analysis and recommendation by ETC/de Leeuw (personal 
communication)
Radon No trend Changes in building stock and construction structures extremely slow
TABLE 4-5. Estimated exposures for 2010 for second-hand smoke in children and non-smoking adults.
Year 2010 Children Adults Women Men
Lower* 
[%]
Upper* 
[%]
Lower 
[%]
Upper 
[%]
Lower 
[%]
Upper 
[%]
Lower 
[%]
Upper 
[%]
Belgium NA NA 25 30 24 29 25 31
Finland 3 NA 14 14 14 14 14 14
France 17 27 13 22 15 25 11 19
Germany 20 NA 20 28 19 27 21 29
Italy 29 NA 22 26 19 23 24 28
Netherlands 14 28 18 27 16 23 21 31
NA: Adequate data not available
* Lower and upper estimates correspond to different computations of survey data.
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5 Uncertainties and limitations
Assessment of uncertainties is essential in a comparison of quantitative estimates that are based on data 
from heterogeneous sources and slightly varying methods. Due to the wide range of data sources and 
models and the limited resources within the EBoDE project, systematic analysis of all uncertainties was 
not possible. However, we were able to assess a number of specific sources of uncertainties in more detail 
as part of the work, yielding some insights into the reliability of the overall assessment.
The studied health impacts span approximately four orders of magnitude in size from few DALYs per 
million to almost 10 000 DALYs per million. The overall ranking of the environmental stressors seems to 
be rather robust against the relatively large uncertainties in individual estimates or methodological choices 
like discounting and age-weighing. However, some of the estimated ranges are overlapping. This concerns 
especially second hand smoke, radon and transportation noise that compete for the questionable honour 
of being the second most important environmental stressor in the participating countries. Among these 
stressors the differences are smaller than the corresponding uncertainties of the estimates.
The health state of an individual person is the result of a complex mixture of genetic, environmental 
and behavioural factors. In a typical case of death, numerous factors play together. This means, for example, 
that a single death caused by a cardiovascular disease could be avoided by either reducing air pollution, or 
a better diet, or more physical activity. Therefore, if the individual attributable fractions are summed over 
a number of risk factors, a value over 100% may sometimes be found. For this and other reasons, it has 
been argued that death counts are not suitable for quantification of the impacts (Brunekreef et al., 2007). 
Therefore the authors recommend to mainly use aggregate population measures of health like DALYs, 
YLLs and YLDs.
This chapter presents the quantitative results for selected sources of uncertainties and discusses the 
project limitations and author judgment of the reliability of the ranking. 
Uncertainties per stressor and comparison with other studies
A list of the most important sources of uncertainty for each stressor in the EBoDE calculations is provided 
in Table 5-1. Some of these are further explained below. In addition, we will compare our estimates to 
results of a selection of similar studies. Comparison of different studies on environmental burden of 
disease helps to understand the role of various methodological and strategic selections made in each study, 
like the selection of stressors or health endpoints. 
Benzene. No international burden of disease study utilizing DALYs for benzene was identified. Some studies 
using exposure proxies like proximity of gasoline stations have studies health impacts with inconsistent 
results.
Dioxins. Our calculations were based on the same approach as applied earlier by Leino et al (2008), but 
we utilized an updated cancer slope factor that is approximately seven times higher than the one used by 
Leino et al. Leino et al. did the calculations for Finland only. The work presented here also updated the 
exposure estimates in order to allow for good international comparability, yet some differences between 
the national intake estimation methods remained.
SHS. Our burden of disease calculation for SHS  was based on a WHO model (Öberg et al., 2010). The 
exposure estimates were updated against available national and international data sources for the target 
year 2004, but otherwise the results are comparable with the WHO assessment. Other recent estimates of 
burden of disease for SHS were also available for Germany (Heidrich et al. 2007; Keil et al. 2005), which 
provided similar results as the current estimates.
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Formaldehyde. No international burden of disease study utilizing DALYs for formaldehyde was identified. 
WHO Guidelines for Indoor Air Quality used eye irritation as the main health end-point in setting a 
safe exposure level. However eye irritation cannot be directly used as a health end-point in burden of 
disease calculation because no disability weight exists and therefore was not accounted for here. Scientific 
evidence on the association between formaldehyde and childhood asthma is not considered sufficiently 
consistent yet; thus the results presented here must be taken as provisional estimates of the magnitude of 
the health impacts, to be confirmed by future studies.
Lead. The calculation focused on mild mental retardation and hypertensive disease only. WHO EBD 
estimates (Fewtrell et al., 2003) include cerebro-vascular and other cardiovascular diseases besides 
hypertensive disease; therefore the current estimates for lead are slightly lower than the WHO estimates.
Transportation noise. Burden of disease estimation for transportation noise is currently under active 
development. The estimates presented here were based on the only available international exposure data 
source, the first stage version of the European Noise Directive database (2007), which is not conclusive 
yet. Therefore it is clear that most of the exposures for transportation noise are underestimated. In some 
studies annoyance and cognitive impairment have been used as an additional health end-points for 
environmental noise. However, due to the selected more limited definition of ‘health’ as ICD-classified 
health states used in our assessment, annoyance and cognitive impairment were not included here. Only 
road, rail and air traffic exposures were included; many other sources also contribute to the noise exposures. 
Low exposures below the END data collection limits (50 and 55 dB) were not included. For these reasons it 
can be expected that when these limitations are solved, the impact estimates will increase.
PM and ozone. The methodology developed in Clean Air for Europe -project (CAFE) (Hurley et al., 2005) 
was applied using updated exposure estimates. The updated exposures are based on ambient air quality 
monitoring data that contain, besides the anthropogenic components that CAFE focused on, also natural 
sources of PM
2.5
. The spatial resolution of the updated model is 25 times higher (grid size 10x 10 km² 
instead of 50x50 km²). Compared to the CAFE estimates the current work adds estimation of the impacts 
in DALYs. The WHO Environmental Burden of Disease programme uses a non-linear exposure-response 
function (Ostro, 2004) that at higher exposures yields lower impacts than the linear CAFE model. WHO 
also sets a threshold level at 7.5 µg m-3.
Radon. The exposure estimation and dose-response models are based on earlier international analysis 
conducted by Darby et al. (2006). In comparison with that the current work added estimation of the 
impacts in DALYs. Comparison of UR and RR models yielded similar results. The results using the RR 
approach, accounting for the national differences in the background rates of lung cancer, were selected for 
reporting.
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TABLE 5-1. Identified sources of uncertainty in EBoDE calculations.
Excluded health endpoints and 
related assumptions
Exposure data Exposure response 
function
Calculation 
method
Level of 
overall 
uncertainty a)
Likely over- or 
underestimation b) 
Benzene Anaemia; genotoxicity; other 
blood cancers than leukaemia; 
leukaemia morbidity; effects 
on the immune, endocrine and 
nervous system; acute effects. 
All cases of leukaemia assumed 
to be fatal.
Population representativity 
varies
Differences in number of 
dwellings
Different types of measurements 
(indoor/outdoor; in – or 
excluding SHS, etc)
Sampling times differ 
No specific 
relationships for 
children used (i.e. 
same UR used for 
all ages)
UR method 
of calculating 
PAF leads to 
overestimation 
because all 
cases are 
assumed to be 
fatal.
* Underestimation 
due to excluded 
health endpoints, 
but overestimation 
due to UR method
Dioxins (plus 
furans and 
PCBs)
Effects on the immune, 
endocrine, reproductive and 
nervous system; tooth and 
bone defects.
All cases of cancer assumed to 
be fatal.
Indirect exposure metrics
Different measurement methods
Daily intake of food depends 
on age, body weight and eating 
habits
Exposure varies within countries 
(from region to region) 
Uncertain cancer 
slope factor
Assumed additivity 
of the toxicity of 
different types
UR method 
of calculating 
PAF results in 
overestimation 
because all 
cases are 
assumed to be 
fatal.
*** Underestimation 
of non cancer 
effects, 
Overestimation of 
cancer effects (all 
lethal)
Second Hand 
Smoke
Sudden infant death syndrome; 
low birth weight; reduced 
pulmonary function among 
children; acute irritant 
symptoms.
Data from different years 
and consequent temporal 
interpolation
Differing definitions of 
exposures
Data gaps for some countries
ERF from earlier 
decades when 
questionnaire 
responses may 
have been less 
sensitive 
Odds ratios used 
as RR estimates
Various 
assumptions 
made, e.g. 
smokers are 
not susceptible 
to SHS
* Underestimation 
due to excluded 
endpoints
Potential 
overestimation 
due to increased 
questionnaire 
sensitivity
Formalde-
hyde
Acute symptoms; 
nasopharyngeal and sinonasal 
cancers.
Data from different years
Population representativity 
varies
For some countries limited 
national coverage
Limitation in technique to detect 
peak exposures
Shape of ERF
Threshold level
Partly inconclusive 
evidence for the 
endpoint
ERF from <3 yr 
olds; potential 
effects at 
older ages not 
accounted for
Simulation 
of threshold 
exceedances
Selection of age 
groups
*** Underestimation, 
mainly due to 
exclusion of ≥ 
3year olds but also 
not accounting for 
eye irritation
Lead Other cardiovascular diseases 
than hypertensive disease; 
kidney damage; miscarriages; 
other effects of the nervous 
system; declined fertility; 
alterations in growth 
and endocrine function; 
behavioural disruptions; 
hearing-threshold changes; 
hyperkinetic syndrome; lung 
and stomach cancers.
MMR: proxy for all lost IQ 
points
Differences in study year
Differences in studied age group
Incomplete data, temporal 
extrapolation and poorly known 
exposure trends
Threshold level
Shape of ERF
Evidence 
limited at 
prevailing low 
exposure levels
Estimation 
of threshold 
exceedances
** Underestimation 
due to excluded 
end-points
Transport 
noise
Annoyance; cognitive 
impairment, tinnitus
Small proportion of target 
population is covered
Conversion between different 
noise metrics
Different samples
Different data estimation years
Disability 
weight for sleep 
disturbance is 
uncertain
MI vs IHD
** Underestimation 
due to uncovered 
populations and 
exclusion of 
low exposures, 
endpoints and 
noise sources
Ozone Possible long-term effects Spatial interpolation
Impact of urban areas
YLL not known ** Overestimation 
(YLL set to 12 
months)
Underestimation 
due to exclusion 
of potential long-
term effects
Particulate 
matter
Morbidity outcomes evaluated 
using the CAFE simplifications
Total PM (not just anthropogenic 
emissions)
Potential 
threshold level
Unit risk 
simplifications 
for morbidity 
outcomes
* No substantial 
error expected or 
overestimation 
due to inclusion 
of natural 
background
Radon No health endpoints excluded Possible oversampling of 
geographical regions known 
problematic
* No substantial 
error expected
a) Estimated level of overall uncertainty in burden of disease estimates for specific stressor (authors’ judgment):
   * relatively low level
   ** medium level
   *** relatively high level
   This level may deviate from the level of evidence as presented in Figure 4-1, which provides an estimate of the certainty of the underlying knowledge about causality 
b) Authors’ judgment about whether results are likely to over- or underestimate the true EBD, given the uncertainties.
5   Uncertainties and limitations
70 Report 1/2011
National Institute for Health and Welfare (THL)
European Perspectives on
Environmental Burden of Disease
5.1 Effects of age weighing, discounting and lag
When calculating DALYs, it is optional to discount life years gained in the future. When discounting is 
applied, those life years gained in the future are valued less than life years gained immediately. Discounting 
is important in the context of resource allocation. When the return for an investment is delayed, larger 
returns are needed for making the investment feasible. In the case of human life and health, it has been 
argued that it may not be ethical to downscale, as the discounting effectively does, the value of future 
generations. In other contexts, like in debates over nuclear energy, the life of future generations is often 
given a higher priority than the benefits for the current economy. Moreover, children’s health has been set 
as a priority in the European Environmental Health Action Plan (WHO, 2010c), but both discounting and 
age-weighing downscale health impacts in children. Thus, the social preferences behind discounting (and 
age weighing) are not always clear and consistent (Murray & Acharya, 1997).
Discounting leads to lower valuation of impacts that take place later or that last for a long time
in comparison with immediate and brief effects. The lag time, which is the time between the exposure 
to the environmental stressor and the initiation and manifestation of a disease, has not been routinely 
accounted for in discounting procedures. As part of the EBoDE project, we have tested alternative 
approaches for analysis of the impacts of lag times on the conclusions of the study. Therefore we have 
calculated (i) non-discounted non-age weighted estimates (ii) standard WHO discounted (3% per year) 
age-weighted estimates and (iii) discounted estimates supplemented with crude estimates of the lags from 
exposure to the manifestation of the disease. Adding the effect of discounted lag times to the estimation 
further downscales burden of disease estimates for diseases that take longer times to develop. This section 
compares the three approaches and discusses their implications. Overall, the role of discounting is not 
driving the ranking of our results: comparing the three alternative metrics (Figure 5-1), the relative order 
of magnitude between the stressors remains approximately intact. For some stressors like ozone there is 
a very limited effect of discounting lag times, as the health effects occur immediately after exposure and 
affect only the current year. Especially for stressors associated with cancer there is a substantial reduction 
in the burden of disease when discounting the lag time.
The current work demonstrates the potential impact of accounting for lag times by comparing the 
estimates with and without discounting these lag times. For the six countries addressed in EBoDE, the 
ranking of the population weighted averages for the nine stressors (Figure 5-1) is in no case seriously 
affected.
Figure 5-2 presents the effects of discounting, with an without the lag time, on the overall burden 
of disease estimates. Figure 5-3 shows the absolute effects of discounting by stressor and Figure 5-4 the 
relative effects.
FIGURE 5-1. Comparison of non-discounted (orange), discounted (blue) and discounted with lag (red) results.
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FIGURE 5-2. Effect of discounting on the burden of disease estimates (grey dots: discounting without lags; red dots: 
discounting with lags).
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FIGURE 5-3. Absolute effect of discounting in DALYs per million people (no lag).
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Figure 5-4: Relative effect of discounting in DALYs per million people (no lag).
Thus, while it important to harmonize the discounting procedures, the overall ranking of the results seems 
to be relatively robust against discounting when ranking the stressors. Discounting the lag times has the 
highest relative impacts for the cancer outcomes. The highest absolute impact of discounting the lag-times 
concerns the estimates for particulate matter, because so many cases are involved.
5.2 Quantitative estimates of context, model and parameter  
 uncertainty
Additional calculations were performed for selected cases using alternative but realistic choices for some of 
the input parameters or context and model definitions (Table 5-2). With these cases we want to shed some 
light on the potential effects of uncertainties on the modelling results. In this paragraph, we will present 
the results of the calculations based on these alternative choices, and discuss the causes and implications 
of the observed differences. 
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TABLE 5-2: Parameters of alternative calculations. Grey boxes indicate the varied parameters in comparison to the baseline (see Table 3-19).
Stressor Health endpoint Population Exposure estimate
Unit of 
exposure
Type 
of 
ERF
Point 
estimate of 
ERF a)
LCL 
(95%)
UCL 
(95%)
Reference(s) for 
ERF
Thres-
hold
Calcu-
lation 
method b)
Formal-
dehyde
Asthma aggravation Children (<3 yr)
Mean residential 
indoor concentration
µg m-3 RR 1.017 1.004 1.025
Rumchev et al., 
2002
40 1A
60 1A
Nasopharyngeal cancer All
Mean residential 
indoor concentration
µg m-3 UR 1.30 × 10-5 N.A. N.A. Kerns et al., 1983 0 2B
Lead
Hypertensive disease
Adults Blood lead level µg/l UR 2.50 ×10-2 1.7×10-2 3.2×10-2
Fewtrell et al. 
2003
50 2B
Ischemic heart disease
Cerebrovascular disease
Other cardiac diseases
Adults Blood lead level µg/l RR
N.A. (Age- and gender specific 
calculations conducted using a 
separate WHO model)
Fewtrell et al. 
2003
50 1A
Transport 
noise
Myocardial infarction All
Persons exposed to 
exposure categories
Lday16h 
(dB)
OR function function function Babisch, 2006 55 1A
Ischemic heart disease All
Persons exposued to 
exposure categories
Lday16h 
(dB)
OR function function function Babisch, 2006 55 1A
PM2.5
Cardiopulmonary 
diseases
Adults (>30 yr)
Population weighted 
ambient level
µg m-3 RR 1.0077 1.0020 1.0132
Pope et al., 2002, 
WHO, 2006a
2
1A
4
Lung cancers Adults (>30 yr)
Population weighted 
ambient level
µg m-3 RR 1.012 1.004 1.020
Pope et al., 2002, 
WHO, 2006a
2
1A
4
Total mortality (non-
violent)
Adults (>30 yr)
Population weighted 
ambient level
µg m-3 RR 1.0058 1.0020 1.0096
Pope et al., 2002, 
WHO, 2006b
0 1A
PM10
LRS symptoms days
School children 
(5–14 yr)
Population weighted 
ambient level
µg m-3 UR 0.186 0.092 0.277
Hurley et al., 2005, 
WHO, 2006b
0 1A
LRS symptom days
>15 yr with 
chronic LRS
Population weighted 
ambient level
µg m-3 UR 0.13 0.015 0.243
Hurley et al., 2005, 
WHO, 2006b
0 1A
Radon Lung cancer (mortality) All
Residential mean 
level
Bq m-3 UR 6.6 × 10-7 N.A. N.A. Darby et al., 2005 0 2A
a) These exposure response functions are all expressed per 1 unit of exposure.
b) For description of the calculation methods, see paragraph 2.1.
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5.2.1 Formaldehyde: different health endpoints, thresholds and age groups
A sensitivity analysis was performed for Finland in order to assess the effects of changing the selected 
threshold level and target population group. For comparison purposes corresponding estimates were 
calculated for sinonasal cancer, which was excluded as plausible endpoint at the prevailing exposure levels 
in our baseline calculations. The selected population groups and thresholds are presented in Table 5-3.
Results show that the estimated ranges of impacts for asthma and sinonasal cancer are largely 
overlapping, so the selection of the endpoint does not significantly affect the order of magnitude of the 
estimates. For both endpoints, however, the range of estimates spans two orders of magnitude, from below 
10 DALYs in Finland (population 5 million) to above 500 DALYs, which equals to over 100 DALYs per 
million inhabitants. Formaldehyde exposure levels were the highest in Finland in comparison with the 
other countries in this study. The result highlights that the formaldehyde impact model is highly sensitive 
to the selection of target population and setting of the threshold level. The E-R function is based on a 
single study from non-European conditions (Rumchev et al., 2002, Australia), further highlighting the 
significant uncertainty.
TABLE 5-3. Two health endpoints, four threshold levels and three target age groups compared for formaldehyde.
Endpoint and model #
 
Threshold
µg m-3
Population Exposed EBD
DALYAge 
group
million % million
Nasal cancer
Unit risk 
1.30E-05 cases (µg m-3)-1
1 0 All 5.00 100 5.000 450
2 100 All 5.00 2 0.100 30
3 1000 All 5.00 0 0.000 0
Asthma
Relative risk 
1.017 (µg m-3)-1
4 40 <3 yr 0.17 42 0.071 100
5 100 <3 yr 0.17 2 0.003 6.7
6 40 <15 yr 0.85 42 0.357 560
7 100 <15 yr 0.85 2 0.017 38
In conclusion from the uncertainty analysis and accounting for our ‘best’ estimate, it can be stated that 
the impacts from formaldehyde are expected to be low, but we cannot completely exclude the possibility 
of higher impacts.
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FIGURE 5-5. Comparison of alternative burden of disease models for sinonasal cancer (orange) and asthma (blue) in 
Finland. Selection of the effect threshold affects the estimates more than the selection of the health endpoint (th = 
threshold µg m-3).
Figure 5-5 shows results of the alternative models for formaldehyde. Estimates for the burden of disease 
due to cancer, assuming no effect threshold and linear effect, are more than two orders of magnitude 
higher than the corresponding estimates for asthma aggravation. However, there is no scientific evidence 
for cancer effects below industrial occupational exposure levels which are 1–2 orders of magnitude higher 
than the population exposures. Therefore in can be concluded that the risk of underestimating the effects 
of formaldehyde by looking only at asthma is expected to be small.
The formaldehyde model is thus quite sensitive for the selection of threshold levels for cancer effects. 
Setting the threshold at the exposure level at which Rumchev et al. (2002) observed effects, 60 µg m-3, 
yields ten times higher estimates than using the WHO guideline level. Extrapolating Rumchev et al. data 
below the threshold level would lead to four-fold impacts for children below 15 years.
Scientific evidence on the effects at the low levels is weak, but the impacts cannot be completely 
excluded. Thus the impacts estimated for the current WHO guideline level of 100 µg m-3 have a theoretical 
possibility of being underestimates.
5.2.2 Lead: Comparison to WHO modelling tool
For our baseline results, burden of disease calculations for lead were conducted for mild mental retardation 
(MMR) and hypertensive disease (HTD) as health endpoints and using modelling approach 2B (see Figure 
2-1). WHO has developed a tool for estimating the EBD due to lead based on national exposure levels 
that takes three additional health endpoints into account and uses gender and age specific population 
attributable fraction approach (corresponding to EBoDE model 1A, see Figure 2-1) in the calculation 
(Fewtrell et al. 2003). The health endpoints taken into account in the WHO tool include:
• Mild mental retardation
•	 Hypertensive disease
•	 Ischaemic heart disease
•	 Cerebrovascular disease
•	 Other cardiac diseases
Nasal cancer th=100
Asthma th=100, <15 yr
Asthma th=40, <3 yr
Nasal cancer no threshold
Asthma th=40, <15 yr
0 100 200 300 400 500 600
Nasal cancer th=1000
Asthma th=100, <3 yr
Health impact DALY per year
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To estimate the magnitude of the difference in the burden of disease estimates resulting from these two 
approaches, more complete exposure data from Germany were used to calculate the estimates using the 
WHO approach and compared with the EBoDE results in Table 5-4.
TABLE 5-4. Comparative calculations of the EBD due to lead in Germany in 2004 with two different models (all values 
are given in undiscounted DALYs).
Health endpoint WHO model EBoDE model
Mild mental retardation 25 757 19 005
Hypertensive disease 239 370
Ischaemic heart disease 1 397 n.c.
Cerebrovascular disease 773 n.c.
Other cardiac diseases 701 n.c.
Total EBD 28 867 19 375
n.c. these endpoints were not calculated in the EBoDE model
As expected, the WHO model yields a higher overall EBD due to lead in Germany. However, the comparison 
reveals that the three additional endpoints in the WHO model are not the main reason for the overall 
difference, as they account for less than 3 000 DALYs in Germany. In contrast, for mild mental retardation 
the simplified EBoDE method resulted in approximately 7 000 less DALYs than the WHO model. This can 
be explained by different distribution assumptions for lead in the blood of the population between the two 
models. Correspondingly, EBD estimates for hypertensive disease exhibit a considerable relative difference 
due to the different modelling approach (1A vs 2B). This endpoint, however, only contributes marginally 
to overall EBD due to lead.
The assumptions on the distribution of lead in blood within the population is one of the main 
elements of uncertainty in EBD calculations. Ideally the population exposure distribution would be based 
on measured data instead of models and assumptions. Additionally, all five endpoints should be considered 
in future models in order to reduce underestimation.
5.2.3 Noise: myocardial infarction or ischemic heart disease
The  original studies by Babisch (2006, 2008) on noise and health used myocardial infarction as 
indicator of all cardiovascular health effects. However, the current understanding of the mechanistic 
process leading from noise exposure to myocardial infarction (MI) is consistent for associating noise 
exposures with also other forms and symptoms of ischemic heart disease as discussed by Babisch (2008). 
Therefore in the current assessment IHD data were used in conjunction with the relative risks and 
estimated population attributable fractions. 
From the WHO data for EUR A Region it was estimated that 57% of burden of disease from ischemic 
heart disease is caused by myocardial infarctions. The same ratio for assumed for all participating countries, 
resulting a similar ratio in the estimates for MI/IHD. In the baseline calculation it was assumed that the 
relative risk estimated for road traffic noise is applicable for ischemic heart disease, which increases the 
estimate for cardiovascular diseases to 157% and total noise effects by less than 5%, indicating that the 
noise impacts are mainly driven by sleep disturbance.
For sleep disturbance, part of the uncertainties in the burden of disease estimates were modelled 
by calculating the high sleep disturbance (HSD) effects using the best estimate for the disability weight 
(0.07) as well as using the lower and upper confidence intervals (0.04 and 0.09, respectively. (WHO, 2009a, 
2010d)
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5.2.4 Particulate matter: PM10 or PM2.5; total or cause-specific mortality
The particulate matter models allow for estimation of impacts based on both PM
10
 (for which geographically 
much larger data coverage is available) and PM
2.5
 (for which the epidemiological evidence suggests higher 
impacts). Health endpoints for PM can be selected to cover both a variety of morbidity outcomes as well 
as mortality. Furthermore the latter can be estimated in various ways by looking either at total non-violent 
mortality, or cause specific mortality for causes for which the causality is established. The table below 
compares the results of the calculations using alternative model definitions.
TABLE 5-5. Comparison of selection of various health endpoint models for particulate matter (PM2.5 and PM10).
Indicators used: DALYs for particulate matter
(undiscounted, un-age-weighted, per million people, 
aggregated over 6 countries)
PM2.5 cause-specific mortality and PM2.5 cause-specific 
morbidity (original calculation)
7 642
PM2.5 total mortality and PM2.5 cause-specific morbidity 
(COPD+RAD only)
10 242
PM2.5 cause-specific mortality and
PM10 cause-specific morbidity
6 488
PM2.5 total mortality and
PM10 cause-specific morbidity
9 088
It can be seen that the impact for cause specific mortality is somewhat lower than that estimated using 
total non-violent mortality. It can be concluded that the selection of cause specific calculations for the final 
results therefore may represent a slight underestimation of the total impact.
In comparison with the previous Clean Air for Europe (CAFE) assessment (Hurley et al., 2005), 
the current exposure estimates are based on monitoring data and cover both anthropogenic and natural 
sources of particles. WHO Guidelines for Air Quality (WHO, 2006a) concluded that evidence below 10 
µg m-3 levels is very limited due to the fact that at inhabited areas this concentration is mostly exceeded. 
Linear extrapolation to zero has been used, but the possibility of a threshold has also been suggested. In 
the CAFE assessment the problem was circumvented by modelling only the anthropogenic fraction of 
particles, leaving a natural background of 1–3 µg m-3 to alleviate the effects of potential threshold. In the 
current work the burden of disease calculations were repeated with two alternative threshold levels to asses 
the magnitude of the impact of a potential threshold for PM
2.5
 particles (Table 5-6).
TABLE 5-6. Comparison of particulate matter (PM2.5) impacts using alternative thresholds for cardiopulmonary and 
lung cancer morbidity and mortality.
Endpoints Threshold DALYs for PM2.5
(undiscounted, un-age-weighted, per 
million people, aggregated over 6 
countries)
PM2.5 cause-specific mortality and morbidity 
(original calculation)
0 7 642
PM2.5 cause-specific mortality and morbidity 2 6 936
–“– 4 6 217
In Table 5-6 it can be seen that while the inclusion of a threshold decreases the impact estimates, the order 
of the magnitude remains clearly higher than that estimated for the other stressors.
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5.2.5 Radon: UR versus RR modelling
For radon we have compared burden of disease estimates calculated using both a relative risk and a unit 
risk approach. The relative risk approach accounts for the differences in the background disease rates and 
assumes that the impact of the exposure is of relative nature, i.e. increasing the incidence of lung cancer by 
the same percentage per unit exposure. The unit risk approach assumes, erroneously one could claim, that 
the same exposure is always associated with a same number of cases per million inhabitants regardless of 
the background disease rates. 
The comparison shows that the differences between these two models are relatively small, in the order 
of 15%, higher estimates being created using the RR model (see Table 5-7 and Figure 5-6).
TABLE 5-7. Comparison of UR and RR models for lung cancer cases from radon.
Exposure-response function used DALYs for radon
(undiscounted, un-age-weighted, per million people, 
aggregated over 6 countries)
RR = 1.0016 (1.0005–1.0031) per 1 Bq m-3
(original calculation)
834
UR = 6.6 × 10-7 per 1 Bq m-3 722
FIGURE 5-6. Graphical comparison of the estimated number of cancer (UR model) and attributable mortality (RR 
model) cases in the six participating countries.
5.3 Discussion of the limitations of EBoDE-approach
The environmental burden of disease is the fraction of disease burden that can be attributed to selected 
environmental exposures. When estimating the avoidable burden of disease, complications caused by 
natural background exposures, un-avoidable anthropogenic exposures, and multi-causality have to be 
taken into account. Moreover, development of efficient policies has to consider the exposure reduction 
costs against the expected health benefits. Thus environmental burden of disease estimates are an essential 
input to the policy development process, but need to be accompanied by information about effects, 
costs, and feasibility of policy measures, information about environmental equity and in some cases, risk 
perception in the population..
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Based on the qualitative and non-conclusive quantitative estimates of uncertainties presented in 
this chapter, and author judgment, at least the following limitations must be taken into account when 
interpreting the study results and when developing the methods further:
1. Exposure data for selected risk factors vary in their degree of temporal, population, and geographical 
representativity. Full comparability between countries would require harmonized data collection 
procedures to ensure high degree of population representativity and comparability.
2. The current approach is based on scientific evidence on the exposure-response functions; only 
impacts for which sufficient evidence is available in quantitative format have been included. This 
means that the total EBoDE estimate do not include burden of disease for which as yet incomplete or 
only qualitative evidence exists.
3. Estimates of the disease burden could only be performed for risk factors for which sufficient exposure 
data at population level was available.
4. The population based approach allows for the estimation of the total national impacts, but does not 
allow for identifying gender differences or health impacts in specific population groups, e.g. highly 
exposed or those especially vulnerable due to a lower background health status. If sufficient data 
are available for (potentially) vulnerable groups, this could be included in follow-up research. In 
addition, a life table approach (see appendix B) would allow modelling of population dynamics, so 
ageing of the population can be included, because ageing may increase future risks at current exposure 
levels. Currently, efficient use of lifetable models was not possible, because this would require more 
information about the temporal relationships between exposures and the health impacts. Further life 
table modelling is also one of the recommendations for follow-up.
5. Calculations were performed for the year 2004. This was one of the latest years for which exposure 
and health data were already relatively completely available. Time trends of exposure at the national 
level were hard to establish. 
Overall, it is important to understand that DALYs should not be perceived as a fixed and undisputable 
number. It is an indicator of the magnitude of various health effects that allows for crude comparison  of 
impacts across a wide range of effect types and environmental stressors. When interpreting DALYs, the 
methodological complexities and underlying assumptions need to be kept in mind. The representativity of 
our results for some other regions in Europe, where exposures may be very different, is limited. 
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6 Conclusions and recommendations
Development of efficient environment and health policies and evaluation of their success requires 
quantitative information about environmental exposures and their health impacts. Disability adjusted 
life years (DALYs) can be used as an indicator for the environmental burden of disease by expressing 
both morbidity and mortality effects in one number. World Health Organization Global Burden of 
Disease and Environmental Burden of Disease programmes have developed methodologies for estimating 
environmental burden of disease. However, harmonized exposure data and established methods are still 
lacking for a large number of stressors that have relevance in the developed world. The current study aimed 
to test the available methods in six European countries using a harmonized approach. Nine stressors were 
selected that were considered relevant and interesting for Europe. The selection was intended to cover the 
most important environmental causes of public health impacts, but also to cover less important exposures 
that have had high significance in public debate or policy development.
The results showed that the EBD methodology can be used to estimate the burden of disease in a 
harmonized way over a number of stressors and countries. The highest overall public health impact was 
estimated for ambient fine particles (PM
2.5
; annually 6000-9000 non-discounted DALYs per million in the 
six participating countries) followed by second-hand smoke (600-1200) transportation noise (500-1100), 
and radon (600-900). Lower impacts were estimated for dioxins and lead, followed by ozone, all containing 
also larger relative uncertainties. Lowest impacts were estimated for benzene and formaldehyde. 
Quantitative assessment of the various factors affecting the relative ranking of the stressors based 
on their health impact indicated that the ranking of non-overlapping estimates seems rather robust, 
even when the exact numbers contain variable amount of uncertainties. The scientific evidence on the 
causality and quantitative understanding of the exposure-response relationship was considered to have 
highest reliability for fine particles, second-hand smoke, radon and benzene. Medium uncertainties in 
the exposures and exposure response-relationships were identified for noise, lead and ozone. Quantitative 
results for dioxins and formaldehyde were considered most uncertain when evaluating the scientific 
evidence base.
Differences in the representativity of the exposure data affect the comparability of estimates 
between the countries. Well comparable exposure data was available for particulate matter and ozone, 
followed by radon, second hand smoke, benzene, and dioxins. Lowest comparability was found for lead 
and formaldehyde. Transportation noise exposure data collection is well defined in the European Noise 
Directive (END), but the comparability of the data available from the first phase of data collection has not 
reached these standards yet. The comparability of estimates between the stressors is affected also by the 
selection of the health endpoints and the uncertainty in exposure response functions. It is unlikely that 
these differences in health response models could be solved in the near future. 
Environmental burden of disease estimates support meaningful policy evaluation and resource 
allocation. Besides, policy analysis also needs to account for the reduction potential of exposures, and 
other factors such as costs of policy measures and equity issues. The proposed methods for burden of 
disease estimation should be developed further to cover a larger range of environmental factors and health 
impacts and to include a systematic evaluation of uncertainties.
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Appendix  A: Additional results by country
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Belgium
FIGURE A-1. Relative contribution of the nine targeted stressors on the non-discounted environmental burden of 
disease in Belgium.
TABLE A-1. Results aggregated per stressor in Belgium.
Total DALYs DALYs per million
non-
discounted
discounted
with lag
non-
discounted
discounted
with lag
PM2.5 106 988 47 024 10 462 4 598.3
SHS 11 349 5 289 1 110 517.2
Radon 11 028 2 294 1 078 224.3
Dioxins 4 628 1 745 453 170.7
Traffic noise 4 467 3 292 437 321.9
Lead 3 044 927 298 90.6
Ozone 530 523 52 51.2
Benzene 25 12 2.5 1.1
Formaldehyde 2 1 0.2 0.1
Total 142 062 61 107 13 892 5 975
SHS
Radon
Dioxins
Traffic noise Lead Ozone
Benzene
Formaldehyde
Belgium
PM2.5
Appendix A
89Report 1/2011
National Institute for Health and Welfare (THL)
European Perspectives on
Environmental Burden of Disease
Finland
FIGURE A-2. Relative contribution of the nine targeted stressors on the non-discounted environmental burden of 
disease in Finland.
TABLE A-2. Results aggregated per stressor in Finland.
Total DALYs DALYs per million
non-
discounted
discounted
with lag
non-
discounted
discounted
with lag
PM2.5 24 062 11 146 4 602.3 2 131.8
Radon 4 840 992 925.7 189.8
SHS 4 657 2 326 890.8 444.9
Traffic noise 1 939 1 378 370.8 263.6
Dioxins 1 723 648 329.5 124.0
Lead 618 186 118.3 35.6
Ozone 245 242 46.9 46.4
Benzene 16 7 3.0 1.4
Formaldehyde 9 7 1.6 1.3
Total 38 108 16 933 7 289.0 3 238.8
SHS
Traffic noise
Dioxins
Lead Ozone
Benzene
Formaldehyd
Finland
PM2.5
Radon
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FIGURE A-3. Relative contribution of the nine targeted stressors on the non-discounted environmental burden of 
disease in France.
TABLE A-3. Results aggregated per stressor in France.
Total DALYs DALYs per million
non-
discounted
discounted
with lag
non-
discounted
discounted
with lag
PM2.5 277 264 121 242 4 572.0 1 999.3
Traffic noise 89 958 81 432 1 483.4 1 342.8
Radon 69 502 14 759 1 146.1 243.4
Dioxins 35 511 13 528 585.6 223.1
SHS 33 350 17 726 549.9 292.3
Lead 27 959 8 526 461.0 140.6
Ozone 4 940 4 889 81.5 80.6
Benzene 209 96 3.4 1.6
Formaldehyde 5 4 0.1 0.1
Total 538 697 262 201 8 883.0 4 323.7
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FIGURE A-4. Relative contribution of the nine targeted stressors on the non-discounted environmental burden of 
disease in Germany.
TABLE A-4. Results aggregated per stressor in Germany.
Total DALYs DALYs per million
non-
discounted
discounted
with lag
non-
discounted
discounted
with lag
PM2.5 691 732 307 617 8 384.5 3 728.6
SHS 101 909 47 684 1 235.2 578.0
Radon 51 154 10 636 620.0 128.9
Traffic noise 48 770 38 110 591.1 461.9
Dioxins 38 422 14 482 465.7 175.5
Lead 19 377 5 954 234.9 72.2
Ozone 6 062 5 985 73.5 72.5
Benzene 220 101 2.7 1.2
Formaldehyde 5 4 0.1 0.0
Total 957 650 430 574 11 607.7 5 219.0
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FIGURE A-5. Relative contribution of the nine targeted stressors on the non-discounted environmental burden of 
disease in Italy.
TABLE A-5. Results aggregated per stressor in Italy.
Total DALYs DALYs per million
non-
discounted
discounted
with lag
non-
discounted
discounted
with lag
PM2.5 545 543 237 619 9 377.6 4 084.5
SHS 56 746 27 139 975.4 466.5
Lead 55 018 17 530 945.7 301.3
Radon 50 378 10 357 866.0 178.0
Traffic noise 42 728 38 791 734.5 666.8
Dioxins 28 113 10 531 483.2 181.0
Ozone 8 038 7 936 138.2 136.4
Benzene 245 113 4.2 1.9
Formaldehyde 0 0 0.0 0.0
Total 786 808 350 015 13 524.8 6 016.6
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FIGURE A-6. Relative contribution of the nine targeted stressors on the non-discounted environmental burden of 
disease in the Netherlands.
TABLE A-6. Results aggregated per stressor in the Netherlands.
Total DALYs DALYs per million
non-
discounted
discounted
with lag
non-
discounted
discounted
with lag
PM2.5 135 500 59 020 8 322.2 3 624.9
Traffic noise 12 615 10 803 774.8 663.5
SHS 12 201 6 725 749.4 413.0
Radon 7 374 1 526 452.9 93.7
Dioxins 3 936 1 494 241.7 91.8
Lead 3 535 1 067 217.1 65.6
Ozone 547 541 33.6 33.2
Benzene 26 12 1.6 0.7
Formaldehyde 0 0 0.0 0.0
Total 175 734 81 189 10 793.3 4 986.5
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Appendix B: Comparison with life-table model
Impact Calculation Tool (ICT) – Probabilistic health impact analysis 
with life-tables
The reported EBoDE results were calculated based on point estimates and population group averages 
for relevant input parameters. In the case of most stressors, the analysis was based on WHO total burden 
of disease estimates for 2004. This is a relatively simple and handy modelling approach for determining 
and ranking health impacts of different environmental stressors at a given time period. However, more 
advanced life table modelling is required when trying to predict how age and gender specific health 
impacts will change in time as population structure, background mortality risks and exposures change. 
Given the time frame of the EBoDE project, a detailed life table modelling approach was not feasible. 
However, a parallel development project of a probabilistic life table model called Impact Calculation Tool 
(ICT) allowed for a limited comparison of the two modelling approaches and a view on the advantages of 
probabilistic life table modelling.
Impact Calculation Tool (ICT) is a user-friendly modelling tool for quantification of health impacts 
from environmental exposures. It applies dynamic life table modelling for calculation of population 
specific loss of disability adjusted life years (DALY) from an exposure of interest. The model has been 
developed in the context of the EU project INTARESE and the Finnish Academy project CLAIH, and is a 
collaboration between the National Institute of Health and Welfare (THL, Finland), the National Institute 
for Public Health and the Environment (RIVM, the Netherlands), and Netherlands Environmental 
Assessment Agency (PBL, the Netherlands).
ICT allows analysis of health impacts from one environmental exposure in one given population 
at a time. The follow-up period (time period for which impacts are determined), specific mortality and 
morbidity impacts analysed, and the target population can be defined according to the needs of the 
assessment at hand. In one model run, impacts are modelled for a reference, business-as-usual (BAU), 
and one alternative exposure scenario. Impact indicator outputs include age-specific mortality/disease 
cases, life expectancy (age-specific and birth cohort) and age-specific loss of disability adjusted life years 
(DALY, YLL (years of life lost due to mortality), and YLD (years of life lost due to disease)). Both time 
discounting and age-weighting can be applied. All key input data has to be provided by the user. The input 
data requirements include: 
• age-specific population data 
•	 age-specific baseline mortality incidence and morbidity incidence/prevalence data 
•	 birth rate 
•	 exposure levels (reference, BAU, alternative scenario)
•	 exposure-response functions for the health endpoints of interest (relative risk or absolute risk)
•	 severity weights and durations for the morbidity endpoints.
ICT runs in Analytica, which is a modelling software with a user-friendly graphical interface. The software 
enables probabilistic modelling using Monte Carlo simulation and, therefore, advanced uncertainty 
analysis. Full use of the Analytica programme requires a software licence. However, ICT can also be run 
with a free Analytica player, which can be downloaded from www.lumina.com. The player allows the user 
to view to the model contents and calculation specifics, to input data for key parameters, and to calculate 
results and run probabilistic uncertainty analysis. ICT contains a simple user interface, which enables these 
functions without advanced knowledge of Analytica or the model technicalities. 
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Health impact modelling in ICT
Mortality impacts are modelled using dynamic life table approach. First, total mortality risk is modelled 
for the reference and alternative exposure scenarios using the population and baseline mortality data, 
exposure levels and exposure-response functions. Based on the total mortality risk and population input 
data, the future population structure is then projected for each scenario using life table methodology. 
These population projections are applied in determining the age-conditional life expectancies in the 
different scenarios. YLL (years of life lost due to mortality) can subsequently be calculated directly from 
the life tables as the difference in the life years lived by the projected populations in different scenarios, 
or indirectly based on the age-specific attributable deaths and age-specific life expectancies in a given 
scenario.
In the case of morbidity impacts, the morbidity risk attributable to the exposure is first modelled for 
each scenario based the population and baseline morbidity data, exposure level and exposure-response 
functions. Number of attributable morbidity cases is then calculated using the attributable morbidity 
risk and the modelled population projections for each scenario, and YLD (years of life lost due to disease) 
subsequently based on the attributable cases, severity weight and duration.
Benefits of life table modelling
The advantage of dynamic life table modelling in health impact assessment is that it enables to predict 
impacts in a real life population over time as the population structure and risk level changes. Full use of a 
life table model takes into account that changing the risk of a certain cause of death at a given point in time 
will affect the population available to die from any cause of death at later time points. Thus, it gives the net 
change in the life years saved or lost over time and prevents over-estimation of the overall mortality impact 
when evaluating effects from multiple mortality endpoints for a single exposure or combined mortality 
effects from multiple exposures.
Life table modelling provides most benefits in terms of estimating the net total impacts in a real life 
population when used in a direct way, i.e. comparing the life tables and life years predicted for different 
scenarios. However, the indirect use, i.e. when life table modelling is used to determine age-conditional 
life expectancy in a real life population, which can be further multiplied with attributable deaths to derive 
YLL, can be more preferable in some situations. This is, for example, in cases where impacts are modelled 
for a short follow-up period (one or few years), but the aim is to estimate total loss of life years due 
to the attributable deaths. A simplified solution would be to use age-conditional life expectancy data 
for the current population. However, if the aim is to model impacts due to an existing risk factor, this 
approximation would lead to underestimation of YLL because it ignores that in the (theoretical) absence 
of the risk life expectancy would, in fact, be a fraction higher. In many cases this difference would be 
negligible, but could in some cases be of importance. This source of bias is avoided when applying life table 
modelling in the impact assessment, because the model also predicts the impact of the risk factor to the 
current life-expectancy in the target population.
ICT vs. EBoDE modelling approach
To compare results from ICT modelling with the results from the more simple modelling approach 
applied in EBoDE, and to demonstrate possibilities for further impact analysis with life table modelling, 
health impacts from fine particle (PM2.5) exposure in Finland were calculated with ICT. Impacts were 
modelled for a 40 year follow-up period starting from 2004. The indirect impact calculation approach 
(YLL is calculated from age-specific attributable deaths and age conditional life expectancies) was used in 
order to express the annual loss of life years in a way that is comparable with the EBoDE results. Modelling 
was based on the same exposure level, exposure-response functions, time discount factor and age weights 
as in the EBoDE model. Population and baseline mortality incidence data used was for year 2004. 
Health impacts modelled using the EBoDE approach and ICT are compared in Table B-1. As expected, 
the differences are small. In principle, the EBoDE modelling approach should yield somewhat higher 
mortality impact values, because the model is based on the WHO total burden of disease data for 2004. In 
WHO burden of disease method, YLL is calculated based on age-conditional standard life expectancies, 
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which are a little bit higher than age-conditional life expectancies in the real Finnish population used in 
ICT. However, all the EBoDE impact estimates are lower, most likely dueto discrepancy in the mortality 
incidence data used in the ICT modelling and WHO 2004 burden of disease calculations or difference in 
the specifics of how age-specific death counts and life expectancies are combined to yield YLL in ICT and 
WHO burden of disease. 
TABLE B-1. Burden of disease from different mortality and morbidity impacts due to PM2.5 exposure in Finland in 2004.
Health end-point
Non-discounted, non-ageweighed 
DALYs
Discounted and age-weighted DALYs
EBoDE ICT Difference EBoDE ICT Difference
Cardiopulmonary mortality 13 599 14 572 973 6 401 6 646 245
Lung cancer mortality 2 856 2 988 132 1 407 1 434 27
Total mortality 25 321 27 088 1 767 12 151 12 597 446
Restricted activity days (RAD) 776 777 0 776
a 908 131
Lower respiratory symptom days 
(LRS), children
425 425 0 425a 414 -12
Lower respiratory symptom days 
(LRS), adults
607 606 0 607a 641 34
a In EBoDE calculations age-weighing was not used for PM
2.5
 morbidity outcomes due to causes related to model 
implementation. Difference to ICT results indicate the magnitude of these impacts.
ICT allows probabilistic impact modelling using Monte Carlo simulation, which enables advanced 
uncertainty analysis. Instead of determining only the upper and lower estimates to give the possible range 
of impacts, with probabilistic modelling one can get information on the likelihood of the estimates within 
that range. As an example, Figure B-1 shows a cumulative probability curve for the years of life lost from 
cardiopulmonary and lung cancer mortality impacts. Probabilistic analysis requires one or more key 
model inputs to be defined as probability distributions. In the example, the exposure-response functions 
were defined as following distributions: cardiopulmonary mortality: triangular(min 1.02, mode 1.08, max 
1.14), lung cancer mortality: triangular(min 1.04, mode 1.13, max 1.22)
FIGURE B-1. Cumulative probability curve for total years of life lost from cardiopulmonary and lung cancer mortality 
due to PM2.5 exposure in Finland in 2004 (no time discounting, no age weighting).
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ICT automatically provides age-specific impact estimates. Figures B-2 and B-3 show how the mortality 
impacts from PM2.5 exposure are distributed among age groups.
FIGURE B-2. Years of life lost in different age groups from total mortality (non-accidental) due to PM2.5 exposure in 
Finland in 2004. nd = no discounting or age weighting, d+aw = time discounting and age weighting applied.
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FIGURE B-3. Years of life lost (no time discounting or age weighting) in different age groups from cardiopulmonary 
and lung cancer mortality due to PM2.5 exposure in Finland in 2004.
The main benefit of life table modelling is that it allows predicting how impacts in a real life population 
will change in the future as the population structure changes. As an example, Table B-2 and Figures B-4 
and B-5 show how health impacts from PM
2.5
 would change in time in the Finnish population, should the 
exposure stay on the 2004 level. Population projections require assumptions on the future birth rate. In 
this case birth rate for the years 2004-2009 was based on the Finnish birth statistics and for the years 2010–
2043 the rate was assumed to stay on the 2009 level. In addition to population age structure, future impacts 
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depend on how the exposure level and background mortality risk change in time. In ICT, it would also be 
possible to model impacts for a situation where the exposure level changes through the follow-up time. 
TABLE B-2. Burden of disease (no time discounting or age weighting) due to total mortality (non-accidental) due to 
PM2.5 exposure in Finland when exposure is assumed to stay on the 2004 level.
 
Age 
group
Years
2004–
2008
2009–
2013
2014–
2018
2019–
2023
2024–
2028
2029–
2033
2034–
2038
2039–
2043
0-29  -  -  -  -  -  -  -  - 
30-34  1 143  1 182  1 160  1 155  1 126  1 039  1 023  1 055 
35-39  2 507  2 372  2 455  2 408  2 398  2 337  2 158  2 124 
40-44  4 480  4 018  3 802  3 935  3 860  3 844  3 746  3 459 
45-49  7 231  6 946  6 230  5 895  6 101  5 985  5 960  5 808 
50-54  11 265  10 781  10 355  9 287  8 789  9 096  8 922  8 885 
55-59  14 832  14 182  13 573  13 037  11 693  11 065  11 452  11 233 
60-64  15 866  18 348  17 545  16 791  16 128  14 465  13 689  14 167 
65-69  14 966  18 680  21 603  20 656  19 769  18 988  17 031  16 117 
70-74  16 876  17 921  22 368  25 867  24 734  23 672  22 737  20 393 
75-79  18 035  18 762  19 924  24 868  28 758  27 498  26 317  25 278 
80-84  16 873  18 338  19 076  20 258  25 285  29 240  27 959  26 758 
85-89  11 281  13 838  15 039  15 645  16 614  20 737  23 980  22 930 
90-94  5 052  6 281  7 705  8 374  8 711  9 250  11 546  13 352 
95+  1 327  1 628  2 024  2 482  2 698  2 806  2 980  3 720 
Total  141 733  153 277  162 857  170 659  176 663  180 023  179 500  175 279 
FIGURE B-4. Years of life lost (no time discounting or age weighting) from cardiopulmonary and lung cancer mortality 
due to PM2.5 exposure in Finland from 2004 to 2043.
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FIGURE B-5. Years of life lost (no time discounting or age weighting) from morbidity due to PM2.5 exposure in Finland 
from 2004 to 2043. RAD = restricted activity days (age group 15–64), LRS = lower respiratory symptom days (children 
aged 5–14, adults aged >15).
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